Feasibility of Identifying Factors Related to Alzheimer’s Disease and Related Dementia in Real-World Data

Aokun Chen, Qian Li, Yu Huang, Yongqiu Li, Yu-neng Chuang, Xia Hu, Serena Guo, Yonghui Wu, Yi Guo, Jiang Bian
doi: https://doi.org/10.1101/2024.02.10.24302621

ABSTRACT

A comprehensive understanding of factors associated with Alzheimer’s disease (AD) and AD-related dementias (AD/ADRD) will significantly enhance efforts when designing new studies to develop new treatments and identify high-risk populations for prevention. We reviewed existing meta-analyses and review articles on AD/ADRD risk and preventive factors, extracting 477 risk factors across 10 categories from 537 studies. An interactive knowledge graph was created to share our study findings. Most risk factors can be found in structured Electronic Health Records (EHRs), with clinical narratives also providing valuable information. However, assessing genomic risk factors using real-world data (RWD) like EHRs remains a challenge, as genetic testing for AD/ADRD is still not a common practice and poorly documented in both structured and unstructured EHRs. Given the constant and rapid evolution of AD/ADRD research, using natural language processing (NLP) for literature mining emerges as a viable method to continually and automatically update our knowledge graph.

Introduction

Alzheimer’s disease (AD) and AD-related dementias (AD/ADRD) are progressive neurodegenerative illnesses that cause memory loss and other cognitive impairments. In the United States, there are currently an estimated 6.7 million patients living with AD. This number is expected to double by 2060, reaching 13.8 million [1]. Despite being a national focus through initiatives like the National Alzheimer’s Project Act and significant investments, there is still no effective treatment or preventive strategy. The few pharmaceutical treatments available primarily aim to alleviate symptoms, such as improving cognition, behavior, and global function; however, these improvements are modest at best [2]. Recently, new anti-amyloid antibody therapies, such as Aducanumab and Lecanemab, were approved by the U.S. Food and Drug Administration (FDA). These drugs have shown promising efficacy in clinical trials data [3,4], yet concerns about their real-world effectiveness and controversies have arisen [5–7], especially concerns on whether their limited efficacies reported in trials are clinically meaningful but also discussions on how to appropriately use these treatment in real-world clinical settings [8–10].

The complex mechanisms involved in the pathogenesis of AD/ADRD remain unclear. It is speculated that AD/ADRD results from a complicated interplay of brain changes associated with various age, genetic, environmental, and lifestyle factors. Although abundant literature exists on different factors, either as risks or protective elements, related to AD/ADRD from wet lab to population science studies, a comprehensive overview encompassing all these factors is lacking. Previous studies have often focused on subsets of these factors from specific types or categories, such as genetic or environmental influences [11–15]. A comprehensive view of factors associated with AD/ADRD will significantly aid in studies to develop new treatments for AD/ADRD and identify high-risk populations and patients for prevention efforts.

The wide adoption of electronic health records (EHRs) has made large collections of real-world data (RWD) [16,17] and detailed patient information available for research. This includes sociodemographic data, lab tests, medications, disease status, and treatment outcomes, offering unique opportunities to generate real-world evidence (RWE) that reflects the patients’ treated in real-world settings. EHRs typically contain structured data, often coded (e.g., diagnoses coded in International Classification of Diseases). However, over 80% of information in EHRs is documented in free-text clinical narratives, such as physicians’ notes and radiology reports [18]. These narratives contain detailed patient characteristics including important AD/ADRD risk factors, such as apolipoprotein E (APOE) and social determinants of health (SDoH), that are often not coded in structured EHR data. They also offer more fine-grained outcomes, such as scores from cognitive assessments like the Mini-Mental State Exam (MMSE) and Montreal Cognitive Assessment (MoCA), which help the determine severity of dementia. For example, in a previous study, we have assessed the documentation of cognitive tests and biomarkers for AD/ADRD in unstructured EHRs and developed natural language processing (NLP) pipelines to extract them into discrete values for downstream studies.

In our study, we summarized the risk factors for AD/ADRD by reviewing existing meta-analyses and review articles on risk and preventive factors for AD/ADRD. Compared with the previous studies [19–24], our work provides a updated review of recent publications on AD/ADRD-related risk factors. Drawing from this literature review and identified AD/ADRD factors, we explored the accessibility of these risk and preventive factors in both structured and unstructured EHR data. To disseminate our study results, we also constructed an interactive knowledge map that can be used to aid in the design of future AD/ADRD studies that aim to leverage large collections of RWD to generate RWE.

Methods

Our study consisted of four steps: literature screening, full-text extraction, knowledge graph generation, and accessibility assessment, as depicted in Figure 1. We first searched and screened titles and abstracts from relevant literature databases using a predefined set of keywords. We then performed full text extraction on the selected literature on risk factors for AD/ADRD. With the extracted AD/ADRD risk factors, we constructed a knowledge graph and visualized these factors and their interrelationships. Finally, we examined the accessibility of these AD/ADRD risk factors based on a RWD dataset from the University of Florida Health (UF Health) Integrated Data Repository (IDR), with a specific focus on those factors not readily available in structured EHRs, but in unstructured clinical narratives.

Figure 1.
Figure 1. The overall workflow of the study.

Literature search strategy and screening

Our literature review process adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. To thoroughly identify known risk or protective factors related to AD/ADRD, we conducted searches in three electronic bibliographic databases— PubMed, Cochrane, and Embase—focusing on reviews, systematic reviews, and meta-analysis articles published in the most recent decade. We included two sets of keywords: (1) those related to AD/ADRD (e.g., “Alzheimer’s disease,” “Alzheimer’s and related dementias,” “ADRD,” “Lewy body,” “vascular dementia,” “frontotemporal dementia,” and “dementias”) and (2) those related to risk or protective factors (e.g., “risk factor,” and “prevention”). We excluded case reports, non-human studies, studies of factors not directly associated with dementia, and non-English literature from the search results. We conducted two rounds of screening: title/abstract screening and full-text screening. In each round, at least two reviewers independently reviewed the materials, with any conflicts resolved by a third reviewer.

Full-text risk factor extraction

We developed an information extraction form to document the risk factors and their relationships with the outcomes of interest reported in each article. The relationship should include three components: the factor, the outcome, and the effect, formulating a triple statement in the format of a subject-predicate-object expression. For example, one article reported, “A meta-analysis of studies in normal individuals detected that higher adherence to the MedDiet was associated with lower risk for Alzheimer’s disease (AD) (HR = 0.64; 95 % CI:0.46, 0.89)” [25]. Here, the factor is “higher adherence to the MedDiet”, the outcome is “risk for Alzheimer’s disease”, the effect is “decreased risk significantly,” and the triple is “higher adherence to the MedDiet”- “decreased (significantly)” – “risk for Alzheimer’s disease.” After extraction, we developed standardized categories for each component to summarize the factors, outcomes, and the effects of the factors on the outcomes (Table 1).

View this table:
Table 1. Standardized categories for the risk factors, outcomes, and the effects of the factors on the outcomes.

Knowledge graph construction

With the triples extracted from literature, we created a knowledge graph on ADRD risk factors using Neo4j. This knowledge map encompasses the risk factors, associated outcomes, source literature, categories, and their effects on AD/ADRD risk. We have made this knowledge graph available in an open-access domain to facilitate the exploration of our review results by other researchers.

Assessment of data availability in electronic health records (EHRs)

We evaluated the data availability of the extracted AD/ADRD-related factors based on the EHRs of an AD/ADRD patient cohort retrieved from the University of Florida (UF) Health Integrated Data Repository (IDR). UF IDR is a clinical data warehouse of UF Health clinical and research enterprises. It consolidates information from various clinical and administrative information systems, including the Epic EHR system, into the IDR data warehouse. The IDR contains more than 2 billion observational facts pertaining to more than 2 million patients. Our assessment consisted of two parts, reflecting the nature of EHR data, (1) structured and coded EHRs, and (2) unstructured clinical narratives such as physicians’ progress notes and various reports.

For structured EHR data, we considered two layers of availability: (1) whether the data model can capture the information, and (2) whether the information is actually present in the data. We considered two widely used Common Data Models (CDMs): the National Patient-Centered Clinical Research Network (PCORnet) CDM, and the Observational Medical Outcomes Partnership (OMOP) CDM, as UF Health is part of the OneFlorida+ Clinical Research Consortium contributing to the national PCORnet [26]. According to the two CDMs, we determine that the data model can capture the factors if the data fields are directly available (e.g., age, gender) or if the factors could be queried using standardized codes (e.g., International Classification of Diseases [ICD] codes for conditions and diseases). For each factor that can be formalized into a medical coding system (e.g., ICD codes, Current Procedural Terminology [CPT] codes, Healthcare Common Procedure Coding System [HCPCS] codes, Logical Observation Identifiers Names and Codes [LOINC], RxNorm codes, or National Drug Code [NDC]), we map the factors to the coding system in the data following PCORnet and OMOP CDMs. When then query UF Health IDR to determine whether the risk factors are actually being documented in EHRs.

Some risk factors, such as cognitive tests like MMSE and MoCA, may only be documented in clinical narratives. To assess the availability of each risk factor in unstructured EHR data, we first developed a set of keywords considering various variations, including known abbreviations and synonyms, of how the risk factors would be documented in clinical notes, using a snowballing approach. Using a set of seed keywords (e.g., “MMSE,” “Mini-Mental State Exam”, etc), we searched the keyword patterns in the clinical narratives, reviewed a random sample (n=20) of the hits, and determined whether each sample contain the information about the risk factor of interest. We calculated the precision (i.e., number of notes that does contain the risk factor over the total number of sampled notes) and eliminated keyword patterns that have high false positive rates.

During this process, we also added new keyword patterns (e.g., a new synonym that we did not capture). We iterated these steps until we did not find any new keyword patterns for each factor.

Results

A total of 1,308 studies from the last decade were identified from the literature databases. After de-duplication, 1,094 studies remained. Figure 2. shows our review procedure in a PRISMA flow diagram. The search yielded 537 distinct studies focused on identifying ADRD-related risk factors.

Figure 2.
Figure 2. Our overall literature search and review procedure according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.

AD/ADRD risk factors in RWD literature

In total, we extracted 477 risk factors in 10 categories from the identified studies. Detailed statistics on these risk factors is shown in Table 2.

View this table:
Table 2. Summary statistics of AD/ADRD risk factors extracted from literature.

Genomic-related risk factors reported in the literature for AD/ADRD typically involve gene mutations and alleles that could affect the incidence and outcome of the disease. We identified 88 unique genomic-related AD/ADRD risk factors from 55 studies [27–80]. Among these, 81 were reported to be related to the risk of AD, 2 on vascular dementia, and 5 on other types of dementia. Out of these studies, 40 reported genomic risk factors that increased the risk of AD/ADRD [27,28,32–36,39–42,44,46–50,53,54,56,58–65,67,72–81], 17 reported non-significant effect [29,37,38,51,55,60,62,70,71], 4 indicated genomic-related risk factors that lower AD/ADRD risk [57,65,66,68], and 1 reported inconsistent results [31]. The most frequently reported genomic-related risk factors is the apolipoprotein E (APOE) gene’s alleles (i.e., APOE, APOE e2, APOE e2/3, APOE e3, APOE e3/4, APOE e4, APOE e4/4), mentioned in a total of 23 mentions. Among the APOE mutations, APOE e3 was consistently reported to lower the risk, and APOE e4 to increase the risk, across various studies, while the effects for the other APOE alleles were mixed.

Disease or condition risk factors refer to other health issues of AD/ADRD patients. We identified 172 unique risk factors from 88 literature. [34,36,69,82–152] Among these, 61 were related to AD, 14 to vascular dementia, and 97 to other types of dementia. Of the 88 studies, 76 reported various diseases and conditions that increased the risk of AD/ADRD [34,36,69,82–85,87–96,98,100–105,107–117,120,121,123–137,139–144,146–148,151,153–161], 13 reported a non-significant effect [91,95,105,109,110,128,145–147,149,150,152,160], 3 studies indicated that certain conditions to lower the risk [114,146,147], and 9 reported inconsistent results [14,86,97,99,106,118,122,138,158]. The five most frequently analyzed conditions included depression (mentioned in 31 studies), diabetes (i.e., type 1 and type 2 diabetes, in 27 studies), traumatic brain injury (14 studies), hypertension (14 studies), and anxiety (13 studies). In the surveyed literature, depression (with 29 studies reported an increased risk of AD/ADRD vs. 2 inconsistent), diabetes (25 increase vs. 1 inconsistent vs. 1 decrease), hypertension (12 increase vs. 2 inconsistent), and anxiety (9 increase vs. 4 inconsistent) were reported to increase the risk of AD/ADRD. Traumatic brain injury showed mixed outcomes, with 7 studies reporting an increased risk of AD/ADRD, 6 inconsistent, and 1 a decrease.

Lifestyle risk factors for AD/ADRD include factors such as physical activity, diet, and substance use. We identified 73 unique lifestyle-related risk factors from 42 publications [34,36,69,91,95,109,110,114,120,122,123,158,162–190]. Among these, 43 were related to AD, 6 to vascular dementia, and 53 to other types of dementia. Of the 42 studies, 14 reported lifestyle risk factors increased the risk of AD/ADRD [69,109,110,120,123,158,162,164,178,181,183,184,189,190], 24 indicated a decrease in risk [34,36,69,109,110,114,158,162,163,167,168,170,172–180,182,187,190], and 5 reported inconsistent effects [91,95,106,122,188]. The five most frequently mentioned lifestyle risk factors in the literature were physical activity (mentioned in 23 studies), smoking (19 studies), alcohol (11 studies), Mediterranean diet (9 studies), and diet in general (7 studies). Regarding physical activity, there was a general consensus that an increasing in activity (1 inconsistent vs. 15 decrease) decreased the risk of AD/ADRD, while the impact of inactivity was less clear (3 increase vs. 4 inconsistent). Most studies suggested that smoking increased the risk of AD/ADRD (13 increase vs. 4 inconsistent vs. 2 decrease). Moderate alcohol consumption was generally believed to reduce the risk of AD/ADRD (increase vs. inconsistent vs. decrease = 3:2:6). As for diet, a healthy diet, such as Mediterranean diet, was considered to decrease the risk of AD/ADRD (3 inconsistent vs. 13 decrease), while diets high in saturated fat were reported to increase the AD/ADRD risk in one literature.

Biomarkers are objective measures that can be used to indicate a patient’s medical state accurately and reproducibly, and can be and often used to assess the risk of the patients [191]. We identified 40 unique biomarkers from 24 studies [110,114,155,192–210]. Among these, 39 were found related to AD, 7 to vascular dementia, and 23 to other types of dementia. Of the 24 studies, 26 biomarkers were found to indicate an increased risk of AD/ADRD [109,110,114,192–200,204–210], 2 were associated with a decreased risk [155,203], and 2 showed inconsistent results [122,196]. The seven most studied biomarkers included tau, cholesterol, homocysteine, bone mineral density, magnesium, white matter hyperintensities, and vitamin D level. Most literature reported an increase in tau levels (4 increase vs. 1 inconsistent), homocysteine levels (4 increase), vitamin D deficiency (3 increase), low bone mineral density (2 increase vs. 1 inconsistent), low magnesium levels (2 increase vs. 1 inconsistent), and white matter hyperintensities (2 increase vs. 1 inconsistent) are associated with an increased risk of AD/ADRD. The impact of cholesterol levels was found to be inconsistent in 4 studies.

Medication-related factors, including dietary supplements, refer to the use of medications that could affect the risk of AD/ADRD. We identified 71 unique medication-related risk factors from 48 publications [34,36,69,109,110,114,158,211–249]. Specifically, 62 factors were associated with AD, 3 with vascular dementia, and 41 with other types of dementia. Among these, 3 medications were found to increase the risk of AD/ADRD [69,158,231,250], 45 medications were associated with decreased risk [34,36,69,109,110,114,158,212,217,218,220–222,225,227–230,232–236,238–240,242,244,245,247], 21 showed insignificant results [109,110,158,213–216,219,223,226,228,232,235,237,241,243,248,249,251], and 2 yielded inconsistent results [211,224,246]. The most frequently mentioned medications were statins, antihypertensive medications, Omega-3 Fatty Acids supplement, vitamin E supplements, hormone therapy, and memantine—an antagonist of the N-Methyl-D-Aspartate (NMDA)-receptor used to slow the neurotoxicity that thought to be involved in AD and other neurodegenerative diseases. Most studies reported statins (9 decrease vs. 5 inconsistent), antihypertensive medications (9 decrease vs. 3 inconsistent), vitamin E (3 decrease vs. 2 inconsistent), and memantine (4 decrease) as reducing AD/ADRD risk. The effect of Omega-3 Fatty Acids (1 decrease vs. 4 inconsistent) and hormone therapy (3 increase vs. 3 inconsistent) on AD/ADRD risk were found to be inconsistent.

Procedures in this context refer to medical procedures or non-pharmaceutical interventions that could potentially affect the risk of AD/ADRD. We identified 2 unique procedure-related risk factors from 4 studies [252–255], where neither cognitive training exercises or anesthesia had a significant effect on AD/ADRD risk.

The risk factor of family history pertains to ancestral health patterns that could affect the risk of AD/ADRD. We identified one specific family history risk factor from our review: a family history of Parkinson’s disease [256], however its effect on AD risk was not significant. This also speaks to the fact that family history information is poorly documented in EHRs, leading to limited studies that examined how family history affect AD/ADRD risk.

Environment risk factors refer to aspects of ones’ surroundings (e.g., natural and built environments) that could influence the risk of AD/ADRD. We identified 6 unique environmental factors from 5 studies [109,110,257–261]. Among these, 6 factors were reported in at least 1 publication to increase the risk of AD/ADRD [257–260], one factor was found to decrease AD/ADRD risk [261], and another was reported to have an insignificant effect [109,110]. The three most frequently mentioned environmental risk factors were electromagnetic fields, pesticides, and air pollution, and all of them, electromagnetic fields (4 increase), air pollution (3 increase vs. 1 decrease), and pesticide (3 increase vs. 1 insignificant) were reported to increase the risk of AD/ADRD.

Socioeconomic status factors represent the aspects of social and economic standing that influence an individual’s AD/ADRD risk. We identified 16 unique socioeconomic status risk factors from 13 studies [37,106,109,110,114,116,117,122,158,262–266]. Of these, 6 were reported to affect the risk of AD, while the rest were associated with dementia in general. The most frequently mentioned socioeconomic factor was education, cited in 13 studies. Most of these studies indicated that a higher level of education is associated with a decreased risk of AD/ADRD (15 decrease vs. 5 inconsistent).

Demographic risk factors pertain to the patients’ demographic characteristics that are associated with their AD/ADRD risk. We identified 8 unique demographic risk factors from 10 studies [15,34,36,109,110,122,264,267–269]. Among these, 2 risk factor were related to AD, 1 to frontotemporal dementia, and 5 others were related to the risk of dementia in general. The three most frequently mentioned risk factors are age, sex, and bilingualism. All studies addressing age (increase = 5) reported being elderly increases the risk of AD/ADRD. The effect of sex (3 inconsistent vs. 1 increase) and bilingualism (2 inconsistent) on AD/ADRD risk were found to be inconsistent.

Availability of risk factors in real-world data (RWD)

In addition to surveying the risk factors for AD/ADRD, we also evaluated their accessibility in RWD, especially EHRs. We emphasized risk factors that are not readily available in structured EHRs, but may exist in unstructured clinical narratives, spanning the 10 categories: genomics, condition or disease, lifestyle, biomarker, medication, procedure, family history, environment, socioeconomic status, and demographics. To assess the accessibility of these risk factors, we extracted both structured EHRs and unstructured clinical notes from AD/ADRD patients covering the period from 2012 to 2020 from UF Health IDR. The demographic information of our AD/ADRD cohort can be found in Table 3.

View this table:
Table 3. Demographics of AD/ADRD cohort from University of Florida (UF) Health Integrated Data Repository (IDR).

Among structured EHRs, we identified 250 out of 477 (55.9%) risk factors. Breaking this down by category, we found 171 condition or disease factors (99.42% out of the total 172), 23 biomarkers (57.50% out of 40), 47 medications (66.20% out of 71), 1 procedure-related factor (50% out of 2), and 7 demographic factors (87.50% out of 8) within the structured EHR. However, we were unable to identify any risk factors in the categories of genomics, lifestyle, family history, environment, and socioeconomic status.

We further examined the availability of these risk factors within unstructured clinical narratives. As shown in Table 4, we identified 41 instances of keywords related to AD/ADRD risk factors within the clinical narratives of our AD/ADRD cohort from the UF Health IDR. The top nine most frequently mentioned risk factors among the AD/ADRD patients in clinical narratives included alcohol (96.64%), smoking (96.62%), education (94.24%), activity (i.e., outdoor activity, indoor activity, lack of activity, etc., 92.56%), occupation (88.35%), diet (87.53%), vitamin (75.23%), exercise (e.g., swim, walk, etc. 74.96%), and environment (60.69%). Broken down by the 10 categories, we identified 5 genomic risk factors (5.68% of the 88 genomic risk factors), 14 lifestyle risk factors (19.18% of 73), 3 biomarkers (7.5% of 40), 10 medications (14.08% of 71), 5 environment risk factors (83.33% of 6), 3 socioeconomic status factors (18.75% of the 16), and 1 demographic factor (18.75% of 8) that are available in unstructured EHRs. The summary statistics of the risk factors mentioned in clinical narratives from the UF Health AD/ADRD cohort are summarized in Table 4.

View this table:
Table 4. AD/ADRD risk factors identified in clinical narratives from the UF Health AD/ADRD cohort.

A knowledge graph of AD/ADRD risk factors in RWD

With the risk factors and their relations to outcomes identified from the reviewed studies, we built an interactive knowledge graph using Neo4j—a graph database. This knowledge graph visualizes the risk factors and their related mentions from the literature. The knowledge graph and instructions for setting up the Neo4j can be accessed at https://github.com/uf-hobi-informatics-lab/ADRD_risk_factor_knowledge_map.

With the established triple statements among risk factors and AD/ADRD outcomes mined from the literature, the knowledge embedded in the graph is poised to facilitate the design of new studies on AD/ADRD using RWD. Below, we demonstrate an example of using the knowledge graph to identify ADRD-related risk factors, potential outcomes, and the interconnections between different risk factors. This use case illustrates how researchers can gain a global view of existing AD/ADRD risk factors through the knowledge map and tailor the scope of their investigation accordingly.

Figure 3 shows a global view of the knowledge graph with AD-related factors, where the purple dots are the risk factors, while the red dots indicate related mentions identified from the literature. In total, there are 246 AD-related risk factors from 251 related literature mentions. We can further navigate the knowledge graph to focus on demographic and environmental risk factors related to AD. From Figure 4-a, we can see that the risk of AD increases as the age increases reported in two studies: Hersi et al. [270] and Navipour et al. [124]. Figure 4-b highlights findings from two studies, Angehrn et al. [257] and Rawat et al. [40], suggesting that environmental exposure to electronic fields may contribute to the development of AD. Additionally, two other studies, Nordestgaard et al. [116] and Gunnarsson et al. [271], concluded that pesticide exposure does not have a significant effect on AD.

Figure 3.
Figure 3. An overview of the knowledge graph for AD-related risk factors.
Figure 4.
Figure 4. Demographic and environmental risk factors for AD: (a) illustrates that age is a risk factor of AD, and (b) illustrates that exposure to pesticide does not have significant effect on AD.

Discussion

Through a systematic search of literature that focused on AD/ADRD risk factors from the last decade, we extracted 477 risk factors for AD/ADRD in 10 categories, including genomic (n=88), condition or disease (n=172), lifestyle (n=73), biomarker (n=40), medication (n=71), procedure (n=2), family history (n=1), environment (n=6), socioeconomic status (n=16), and demographics (n=8), from 537 studies that met our criteria. We further analyzed the accessibility of these risk factors in both structured and unstructured (i.e., clinical narratives) EHR data using an AD/ADRD cohort from UF Health IDR. We found that 55.9% of the risk factors, primarily genomic, lifestyle, environment, socioeconomic status factors, were not available in structured EHRs, but do exist in unstructured clinical narratives.

Among the top five mentioned AD/ADRD risk factors, condition or disease-related risk factors were the most frequently studied, with the majority indicating an increased risk of AD/ADRD. Genomic factors ranked second in terms of frequency, with most also reported to elevate AD/ADRD risk. Lifestyle factors were the third most commonly studies category, and these were also predominantly found to increase AD/ADRD risk. Medication factors, the fourth most researched category, were generally found to decrease the risk of AD/ADRD. Biomarker factors, ranking fifth, were mostly reported to associate with an increased risk of AD/ADRD, understandably as these biomarkers are developed to identify or measure AD/ADRD.

Regarding the availability of the top five AD/ADRD risk factors, unsurprisingly a significant portion of condition or disease-related risk factors were accessible from structured EHRs (171 out of 172, 99.42%). This high accessibility likely contributes to their prevalent mention in the literature. In contrast, the availability of genomic risk factors in both structured and unstructured EHR data is limited, despite their frequent mention in the literature; nevertheless, these mentions are mostly focused on the APOE gene—a widely known genetic risk factor for AD. Only 4 genomic risk factors (4.55% out of a total of 88) were only found in clinical narratives of our AD/ADRD cohort from UF Health. The reason is potentially two-fold: (1) genetic testing for AD/ADRD has only become available in the last decade and not yet a routine clinical practice, and (2) genetic tests are often conducted by external labs, with results typically provided in PDF report format rather than being stored discretely in the EHR system. At UF Health, we have only recently implemented the Genomics module in Epic, which is capable of ingesting genetic results from external labs through a standardized interface, thereby making them available in a discrete format. In terms of lifestyle factors, none were retrievable from the structured EHRs. However, from the clinical narratives, we retrieved 14 lifestyle risk factors, accounting for 19.18% out of the total 73, where the most frequently mentioned lifestyle factors include alcohol consumption, smoking, physical activity, and diet. Regarding medication risk factors, 47 (66.20% out of a total of 71) were available from the structured EHRs. These 47 risk factors predominantly involved prescription medicines, making it the second most common category of risk factors sourced from structured EHRs. Additionally, from the clinical narrative, we extracted 10 medication risk factors involving over the counter (OTC) medications, increasing the overall availability of medication risk factors to 80.28%. Among the biomarkers, 23 (57.5% out of a total of 40) were available from structured EHRs. Incorporating the 3 that can be extracted from clinical narratives increased the availability of biomarker risk factor to 65%.

From our observations, we noted a clear trend in the availability of AD/ADRD risk factors within structured EHRs, correlating with their prevalence in literature, except for genomic risk factors. This observation inspires two avenues of future research. First, there is a need for NLP tools to extract AD/ADRD risk factors, especially in the areas of lifestyle, family history, environment, and socioeconomic categories. These AD/ADRD risk factor categories have been under-researched, likely due to limited data availability. Our results indicate that clinical narratives are a promising information source within EHRs. An NLP-based extraction system could greatly enhance data availability in these categories, thereby facilitating research on corresponding risk factors. Second, the integration of other data and information sources with the EHR data is necessary to capture a complete picture of the patient disease development process. For example, genomic factors are the second most researched category, however, they are poorly populated in EHRs. Most current AD/ADRD genomics research data originate from cohorts established by various National Institute on Aging (NIA)-funded consortiums, centers, and repositories [272]. However, these cohorts often lack comprehensive phenotypic information and other critical clinical and socio-environmental factors for modeling AD/ADRD, which are rich in RWD like EHRs. The ability to link and integrate RWD with other data sources, encompassing a broad range of information domains, is critical for future AD/ADRD research. Indeed, the NIA has established the NIA Data LINKAGE Program (LINKAGE) in 2021, aiming to connect NIA-funded study data with other datasets, particularly RWD such as the Medicare claims data from the Centers for Medicare & Medicaid Services (CMS). It also provides a cloud-based Enclave environment to facilitate additional linkages and analyses of these integrated datasets [273].

The knowledge graph needs to be continuously updated, as research on AD/ADRD continues to evolve. However, manually extracting AD/ADRD risk factors from published studies through a systematic scoping review is time-consuming. Literature mining via NLP methods offers an automated way to extract risk factors and relationships from relevant literature, facilitating the discovery of potential connections among AD/ADRD risk factors and outcomes. For example, our previous study [274] demonstrated the effectiveness of employing entity recognition and relation extraction methods to automatically construct a knowledge graph by mining the abstracts of relevant literature. As an illustration, we conducted a search to investigate the relationship between brain trauma and dementia. The results of this search are presented in Figure 5. As depicted in the figure, literature reference #632 [275] suggests that traumatic brain injuries, including mild traumatic brain injuries, are likely to contribute to the development of dementia, with trauma potentially acting as a risk factor for AD-related dementia.

Figure 5.
Figure 5. Relation between brain trauma and dementia mined from literature via natural language process methods.

Our study had limitations. First, we excluded studies not written in English and only focused on reviews, systematic reviews, and meta-analysis articles that were peer-reviewed in the last decade. Consequently, our survey may have missed the most recently published literature. Second, we evaluated the availability of AD/ADRD risk factors based on EHR data from a single health system—UF Health IDR. As data models and documentation patterns vary among different EHR systems and clinical practices, the availability of AD/ADRD risk factors might differ accordingly. Lastly, our evaluation of AD/ADRD risk factors relied on a keyword-based method. This approach may have overlooked some risk factors, as it is impractical to include every possible keywords.

Conclusion

In this study, we conducted a literature review on AD/ADRD risk factors, identifying 10 categories encompassing 477 risk factors. Existing studies predominantly focus on condition or disease-related risk factors, medication risk factors, lifestyle risk factors, and genomic risk factors. Most of the risk factors (including condition, medication, condition, biomarker, and procedure) are accessible from structured EHRs. For those risk factors not accessible from structured EHRs, clinical narratives show promise as information sources, particularly for lifestyle, environmental, and socioeconomic status factors. These narratives also supplement the data on OTC medications and dietary supplements within the category of medication risk factors. However, evaluating genomic risk factors using RWD remains a challenge, as genetic testing for AD/ADRD is still not a common practice as well as being poorly documented in both structured and unstructured EHRs. Our study provides valuable insights and interactive materials to researchers regarding AD/ADRD-related risk factors in RWD and highlights gaps in the field.

Data Availability

The OneFlorida electronic health record data are considered Protected Health Information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA) in the United States, and as such are not publicly-available.

Funding

This study was in part supported by National Institute of Health grants R01AG080991, R56AG069880, R01AG083039, RF1AG084178, R01 AG084236, RF1AG077820, and R01AG080991.

Disclosures/Conflict of Interests

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.

Footnotes

  • The abstract of the paper was updated to clarify the acronyms and improve the writing style.

Reference

  1. [1].↵
    (2023) 2023 Alzheimer’s disease facts and figures. Alzheimers Dement.
  2. [2].↵
    Lanctôt KL, Rajaram RD, Herrmann N (2009) Therapy for Alzheimer’s Disease: How Effective are Current Treatments? Ther Adv Neurol Disord 2, 163–180.
    OpenUrlCrossRefPubMed
  3. [3].↵
    van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T (2023) Lecanemab in early Alzheimer’s disease. N Engl J Med 388, 9–21.
    OpenUrlCrossRef
  4. [4].↵
    Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, Dent G, Hansson O, Harrison K, von Hehn C, Iwatsubo T, Mallinckrodt C, Mummery CJ, Muralidharan KK, Nestorov I, Nisenbaum L, Rajagovindan R, Skordos L, Tian Y, van Dyck CH, Vellas B, Wu S, Zhu Y, Sandrock A (2022) Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J Prev Alzheimers Dis 9, 197–210.
    OpenUrl
  5. [5].↵
    The Lancet (2022) Lecanemab for Alzheimer’s disease: tempering hype and hope. Lancet 400, 1899.
    OpenUrlCrossRef
  6. [6].
    Wolk DA, Rabinovici GD, Dickerson BC (2023) A step forward in the fight against dementia-are we there yet? JAMA Neurol 80, 429–430.
    OpenUrl
  7. [7].↵
    Walsh S, Merrick R, Milne R, Brayne C (2021) Aducanumab for Alzheimer’s disease? BMJ 374, n1682.
    OpenUrlFREE Full Text
  8. [8].↵
    Vaz M, Silva V, Monteiro C, Silvestre S (2022) Role of aducanumab in the treatment of Alzheimer’s disease: Challenges and opportunities. Clin Interv Aging 17, 797–810.
    OpenUrlCrossRef
  9. [9].
    Cummings J, Aisen P, Apostolova LG, Atri A, Salloway S, Weiner M (2021) Aducanumab: Appropriate Use Recommendations. J Prev Alzheimers Dis 8, 398–410.
    OpenUrl
  10. [10].↵
    Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, Hendrix S, Selkoe D, Weiner M, Petersen RC, Salloway S (2023) Lecanemab: Appropriate Use Recommendations. J Prev Alzheimers Dis 10, 362–377.
    OpenUrl
  11. [11].↵
    Oliveira D, Bosco A, di Lorito C (2019) Is poor health literacy a risk factor for dementia in older adults? Systematic literature review of prospective cohort studies. Maturitas 124, 8–14.
    OpenUrl
  12. [12].
    Abyadeh M, Djafarian K, Heydarinejad F, Alizadeh S, Shab-Bidar S (2019) Association between Apolipoprotein E Gene Polymorphism and Alzheimer’s Disease in an Iranian Population: A Meta-Analysis. J Mol Neurosci 69, 557–562.
    OpenUrl
  13. [13].
    Meng X-F, Yu J-T, Wang H-F, Tan M-S, Wang C, Tan C-C, Tan L (2014) Midlife vascular risk factors and the risk of Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimers Dis 42, 1295–1310.
    OpenUrl
  14. [14].↵
    Shen L, Ji H-F (2015) Associations between Homocysteine, Folic Acid, Vitamin B12 and Alzheimer’s Disease: Insights from Meta-Analyses. J Alzheimers Dis 46, 777–790.
    OpenUrl
  15. [15].↵
    Gimson A, Schlosser M, Huntley JD, Marchant NL (2018) Support for midlife anxiety diagnosis as an independent risk factor for dementia: a systematic review. BMJ Open 8, e019399.
    OpenUrlAbstract/FREE Full Text
  16. [16].↵
    Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, LaVange L, Marinac-Dabic D, Marks PW, Robb MA, Shuren J, Temple R, Woodcock J, Yue LQ, Califf RM (2016) Real-world evidence – what is it and what can it tell us? N Engl J Med 375, 2293– 2297.
    OpenUrlCrossRefPubMed
  17. [17].↵
    Concato J, Corrigan-Curay J (2022) Real-world evidence – where are we now? N Engl J Med 386, 1680–1682.
    OpenUrlCrossRefPubMed
  18. [18].↵
    Meystre SM, Savova GK, Kipper-Schuler KC, Hurdle JF (2008) Extracting information from textual documents in the electronic health record: a review of recent research. Yearb Med Inform 128–144.
  19. [19].↵
    Joshi P, Hendrie K, Jester DJ, Dasarathy D, Lavretsky H, Ku BS, Leutwyler H, Torous J, Jeste DV, Tampi RR (2023) Social connections as determinants of cognitive health and as targets for social interventions in persons with or at risk of Alzheimer’s disease and related disorders: a scoping review. Int Psychogeriatr 1–27.
  20. [20].
    Greene AN, Solomon MB, Privette Vinnedge LM (2022) Novel molecular mechanisms in Alzheimer’s disease: The potential role of DEK in disease pathogenesis. Front Aging Neurosci 14, 1018180.
    OpenUrl
  21. [21].
    Vassilaki M, Petersen RC, Vemuri P (2022) Area deprivation index as a surrogate of resilience in aging and dementia. Front Psychol 13, 930415.
    OpenUrl
  22. [22].
    Babulal GM, Rani R, Adkins-Jackson P, Pearson AC, Williams MM (2022) Associations between homelessness and Alzheimer’s disease and related dementia: A systematic review. J Appl Gerontol 41, 2404–2413.
    OpenUrl
  23. [23].
    Balls-Berry JJE, Babulal GM (2022) Health disparities in dementia. Continuum (Minneap Minn) 28, 872–884.
    OpenUrl
  24. [24].↵
    Rubin L, Ingram LA, Resciniti NV, Ashford-Carroll B, Leith KH, Rose A, Ureña S, McCollum Q, Friedman DB (2021) Genetic risk factors for Alzheimer’s Disease in racial/ethnic minority populations in the U.s.: A scoping review. Front Public Health 9, 784958.
    OpenUrl
  25. [25].↵
    Shannon OM, Ranson JM, Gregory S, Macpherson H, Milte C, Lentjes M, Mulligan A, McEvoy C, Griffiths A, Matu J, Hill TR, Adamson A, Siervo M, Minihane AM, Muniz-Tererra G, Ritchie C, Mathers JC, Llewellyn DJ, Stevenson E (2023) Mediterranean diet adherence is associated with lower dementia risk, independent of genetic predisposition: findings from the UK Biobank prospective cohort study. BMC Med 21, 81.
    OpenUrl
  26. [26].↵
    Hogan WR, Shenkman EA, Robinson T, Carasquillo O, Robinson PS, Essner RZ, Bian J, Lipori G, Harle C, Magoc T, Manini L, Mendoza T, White S, Loiacono A, Hall J, Nelson D (2021) The OneFlorida Data Trust: a centralized, translational research data infrastructure of statewide scope. J Am Med Inform Assoc.
  27. [27].↵
    Liang Y, Wang L (2017) Alzheimer’s disease is an important risk factor of fractures: A meta-analysis of cohort studies. Mol Neurobiol 54, 3230–3235.
    OpenUrl
  28. [28].↵
    Abdelhafiz AH, McNicholas E, Sinclair AJ (2016) Hypoglycemia, frailty and dementia in older people with diabetes: Reciprocal relations and clinical implications. J Diabetes Complications 30, 1548–1554.
    OpenUrlPubMed
  29. [29].↵
    Mazzucco S, Diomedi M, Qureshi A, Sainati L, Padayachee ST (2017) Transcranial Doppler screening for stroke risk in children with sickle cell disease: a systematic review. Int J Stroke 12, 580–588.
    OpenUrl
  30. [30].
    Belvederi Murri M, Prestia D, Mondelli V, Pariante C, Patti S, Olivieri B, Arzani C, Masotti M, Respino M, Antonioli M, Vassallo L, Serafini G, Perna G, Pompili M, Amore M (2016) The HPA axis in bipolar disorder: Systematic review and meta-analysis. Psychoneuroendocrinology 63, 327–342.
    OpenUrlCrossRefPubMed
  31. [31].↵
    Power MC, Weuve J, Sharrett AR, Blacker D, Gottesman RF (2015) Statins, cognition, and dementia—systematic review and methodological commentary. Nat Rev Neurol 11, 220–229.
    OpenUrlCrossRefPubMed
  32. [32].↵
    Han X-M, Wang C-H, Sima X, Liu S-Y (2011) Interleukin-6 –174G/C polymorphism and the risk of Alzheimer’s disease in Caucasians: a meta-analysis. Neurosci Lett 504, 4–8.
    OpenUrlCrossRefPubMed
  33. [33].
    Amraei M, Mohamadpour R, Moayeri A, Abbasi N, Shirzadpour E, Mohamadpour M (2017) Vitamin D and its association with memory and learning: A systematic review and meta-analysis. Biomed Res 28, 7427–7433.
    OpenUrl
  34. [34].↵
    Al-Khazraji BK, Appleton CT, Beier F, Birmingham TB, Shoemaker JK (2018) Osteoarthritis, cerebrovascular dysfunction and the common denominator of inflammation: a narrative review. Osteoarthritis Cartilage 26, 462–470.
    OpenUrl
  35. [35].
    Beauchet O, Annweiler C, Callisaya ML, De Cock A-M, Helbostad JL, Kressig RW, Srikanth V, Steinmetz J-P, Blumen HM, Verghese J, Allali G (2016) Poor gait performance and prediction of dementia: Results from a meta-analysis. J Am Med Dir Assoc 17, 482–490.
    OpenUrlCrossRefPubMed
  36. [36].↵
    Ma F-C, Wang H-F, Cao X-P, Tan C-C, Tan L, Yu J-T (2018) Meta-analysis of the association between variants in ABCA7 and Alzheimer’s disease. J Alzheimers Dis 63, 1261–1267.
    OpenUrl
  37. [37].↵
    Simning A, Simons KV (2017) Treatment of depression in nursing home residents without significant cognitive impairment: a systematic review. Int Psychogeriatr 29, 209–226.
    OpenUrl
  38. [38].↵
    Woolford MH, Weller C, Ibrahim JE (2017) Unexplained absences and risk of death and injury among nursing home residents: A systematic review. J Am Med Dir Assoc 18, 366.e1–366.e15.
    OpenUrl
  39. [39].↵
    Witoelar A, Rongve A, Almdahl IS, Ulstein ID, Engvig A, White LR, Selbæk G, Stordal E, Andersen F, Brækhus A, Saltvedt I, Engedal K, Hughes T, Bergh S, Bråthen G, Bogdanovic N, Bettella F, Wang Y, Athanasiu L, Bahrami S, Le Hellard S, Giddaluru S, Dale AM, Sando SB, Steinberg S, Stefansson H, Snaedal J, Desikan RS, Stefansson K, Aarsland D, Djurovic S, Fladby T, Andreassen OA (2018) Meta-analysis of Alzheimer’s disease on 9,751 samples from Norway and IGAP study identifies four risk loci. Sci Rep 8, 18088.
    OpenUrlPubMed
  40. [40].↵
    Rawat S, Jugran AK, Bhatt ID, Rawal RS (2018) Hedychium spicatum: a systematic review on traditional uses, phytochemistry, pharmacology and future prospectus. J Pharm Pharmacol 70, 687–712.
    OpenUrl
  41. [41].
    Farzaei MH, Shahpiri Z, Bahramsoltani R, Nia MM, Najafi F, Rahimi R (2017) Efficacy and tolerability of phytomedicines in multiple sclerosis patients: A review. CNS Drugs 31, 867– 889.
    OpenUrl
  42. [42].↵
    Charemboon T, Jaisin K (2015) Ginkgo biloba for prevention of dementia: a systematic review and meta-analysis. J Med Assoc Thai 98, 508–513.
    OpenUrl
  43. [43].
    Pratap GK, Ashwini S, Shantaram M (2017) ALZHEIMER’S DISEASE: A CHALLENGE IN MANAGING WITH CERTAIN MEDICINAL PLANTS – A REVIEW. International Journal of Pharmaceutical Sciences and Research 4, 4960–4972.
    OpenUrl
  44. [44].↵
    Yorek MA (2017) Is fish oil a potential treatment for diabetic peripheral neuropathy? Curr Diabetes Rev 14, 339–349.
    OpenUrl
  45. [45].
    Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, Weiner M, Aisen PS, Australian Imaging, Biomarkers, and Lifestyle Flagship Study of Ageing, Alzheimer’s Disease Neuroimaging Initiative, Alzheimer’s Disease Cooperative Study (2014) The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol 71, 961–970.
    OpenUrl
  46. [46].↵
    Liu S-Y, Zeng F-F, Chen Z-W, Wang C-Y, Zhao B, Li K-S (2013) Vascular endothelial growth factor gene promoter polymorphisms and Alzheimer’s disease risk: a meta-analysis. CNS Neurosci Ther 19, 469–476.
    OpenUrl
  47. [47].
    Parnetti L, Chipi E, Salvadori N, D’Andrea K, Eusebi P (2019) Prevalence and risk of progression of preclinical Alzheimer’s disease stages: a systematic review and meta-analysis. Alzheimers Res Ther 11, 7.
    OpenUrlCrossRefPubMed
  48. [48].
    Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FRJ, Visser PJ, Amyloid Biomarker Study Group, Aalten P, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel H, van Berckel BNM, Bibeau K, Blennow K, Brooks DJ, van Buchem MA, Camus V, Cavedo E, Chen K, Chetelat G, Cohen AD, Drzezga A, Engelborghs S, Fagan AM, Fladby T, Fleisher AS, van der Flier WM, Ford L, Förster S, Fortea J, Foskett N, Frederiksen KS, Freund-Levi Y, Frisoni GB, Froelich L, Gabryelewicz T, Gill KD, Gkatzima O, Gómez-Tortosa E, Gordon MF, Grimmer T, Hampel H, Hausner L, Hellwig S, Herukka S-K, Hildebrandt H, Ishihara L, Ivanoiu A, Jagust WJ, Johannsen P, Kandimalla R, Kapaki E, Klimkowicz-Mrowiec A, Klunk WE, Köhler S, Koglin N, Kornhuber J, Kramberger MG, Van Laere K, Landau SM, Lee DY, de Leon M, Lisetti V, Lleó A, Madsen K, Maier W, Marcusson J, Mattsson N, de Mendonça A, Meulenbroek O, Meyer PT, Mintun MA, Mok V, Molinuevo JL, Møllergård HM, Morris JC, Mroczko B, Van der Mussele S, Na DL, Newberg A, Nordberg A, Nordlund A, Novak GP, Paraskevas GP, Parnetti L, Perera G, Peters O, Popp J, Prabhakar S, Rabinovici GD, Ramakers IHGB, Rami L, Resende de Oliveira C, Rinne JO, Rodrigue KM, Rodríguez-Rodríguez E, Roe CM, Rot U, Rowe CC, Rüther E, Sabri O, Sanchez-Juan P, Santana I, Sarazin M, Schröder J, Schütte C, Seo SW, Soetewey F, Soininen H, Spiru L, Struyfs H, Teunissen CE, Tsolaki M, Vandenberghe R, Verbeek MM, Villemagne VL, Vos SJB, van Waalwijk van Doorn LJC, Waldemar G, Wallin A, Wallin ÅK, Wiltfang J, Wolk DA, Zboch M, Zetterberg H (2015) Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313, 1924–1938.
    OpenUrlCrossRefPubMed
  49. [49].
    Momtaz S, Hassani S, Khan F, Ziaee M, Abdollahi M (2018) Cinnamon, a promising prospect towards Alzheimer’s disease. Pharmacol Res 130, 241–258.
    OpenUrl
  50. [50].↵
    Hudson M, Nowak C, Garling RJ, Harris C (2019) Comorbidity of diabetes mellitus in idiopathic normal pressure hydrocephalus: a systematic literature review. Fluids Barriers CNS 16, 5.
    OpenUrl
  51. [51].↵
    Tang EY, Amiesimaka O, Harrison SL, Green E, Price C, Robinson L, Siervo M, Stephan BC (2018) Longitudinal effect of stroke on cognition: A systematic review. J Am Heart Assoc 7,.
  52. [52].
    Theoharides TC, Tsilioni I (2018) Tetramethoxyluteolin for the treatment of neurodegenerative diseases. Curr Top Med Chem 18, 1872–1882.
    OpenUrl
  53. [53].↵
    Beckett MW, Ardern CI, Rotondi MA (2015) A meta-analysis of prospective studies on the role of physical activity and the prevention of Alzheimer’s disease in older adults. BMC Geriatr 15, 9.
    OpenUrlCrossRef
  54. [54].↵
    Dong X, Zhang L, Meng Q, Gao Q (2017) Association Between Interleukin-1A, Interleukin-1B, and Bridging integrator 1 Polymorphisms and Alzheimer’s Disease: a standard and Cumulative Meta-analysis. Mol Neurobiol 54, 736–747.
    OpenUrl
  55. [55].↵
    Kok RM, Reynolds CF 3rd. (2017) Management of depression in older adults: A review. JAMA 317, 2114–2122.
    OpenUrlPubMed
  56. [56].↵
    Moulin S, Leys D, Schraen-Maschke S, Bombois S, Mendyk A-M, Muhr-Tailleux A, Cordonnier C, Buee L, Pasquier F, Bordet R (2017) Aβ1-40 and Aβ1-42 plasmatic levels in stroke: Influence of pre-existing cognitive status and stroke characteristics. Curr Alzheimer Res 14, 686–694.
    OpenUrl
  57. [57].↵
    Giannopoulos S, Katsanos AH, Kosmidou M, Tsivgoulis G (2014) Statins and vascular dementia: a review. J Alzheimers Dis 42 Suppl 3, S315–20.
    OpenUrl
  58. [58].↵
    Zheng Y, Fan S, Liao W, Fang W, Xiao S, Liu J (2017) Hearing impairment and risk of Alzheimer’s disease: a meta-analysis of prospective cohort studies. Neurol Sci 38, 233–239.
    OpenUrl
  59. [59].
    Durg S, Dhadde SB, Vandal R, Shivakumar BS, Charan CS (2015) Withania somnifera (Ashwagandha) in neurobehavioural disorders induced by brain oxidative stress in rodents: a systematic review and meta-analysis. J Pharm Pharmacol 67, 879–899.
    OpenUrl
  60. [60].↵
    Lipnicki DM, Makkar SR, Crawford JD, Thalamuthu A, Kochan NA, Lima-Costa MF, Castro-Costa E, Ferri CP, Brayne C, Stephan B, Llibre-Rodriguez JJ, Llibre-Guerra JJ, Valhuerdi-Cepero AJ, Lipton RB, Katz MJ, Derby CA, Ritchie K, Ancelin M-L, Carrière I, Scarmeas N, Yannakoulia M, Hadjigeorgiou GM, Lam L, Chan W-C, Fung A, Guaita A, Vaccaro R, Davin A, Kim KW, Han JW, Suh SW, Riedel-Heller SG, Roehr S, Pabst A, van Boxtel M, Köhler S, Deckers K, Ganguli M, Jacobsen EP, Hughes TF, Anstey KJ, Cherbuin N, Haan MN, Aiello AE, Dang K, Kumagai S, Chen T, Narazaki K, Ng TP, Gao Q, Nyunt MSZ, Scazufca M, Brodaty H, Numbers K, Trollor JN, Meguro K, Yamaguchi S, Ishii H, Lobo A, Lopez-Anton R, Santabárbara J, Leung Y, Lo JW, Popovic G, Sachdev PS, for Cohort Studies of Memory in an International Consortium (COSMIC) (2019) Determinants of cognitive performance and decline in 20 diverse ethno-regional groups: A COSMIC collaboration cohort study. PLoS Med 16, e1002853.
    OpenUrl
  61. [61].
    Matta Mello Portugal E, Cevada T, Sobral Monteiro-Junior R, Teixeira Guimarães T, da Cruz Rubini E, Lattari E, Blois C, Camaz Deslandes A (2013) Neuroscience of exercise: from neurobiology mechanisms to mental health. Neuropsychobiology 68, 1–14.
    OpenUrlCrossRefPubMed
  62. [62].↵
    Riederer P, Korczyn AD, Ali SS, Bajenaru O, Choi MS, Chopp M, Dermanovic-Dobrota V, Grünblatt E, Jellinger KA, Kamal MA, Kamal W, Leszek J, Sheldrick-Michel TM, Mushtaq G, Meglic B, Natovich R, Pirtosek Z, Rakusa M, Salkovic-Petrisic M, Schmidt R, Schmitt A, Sridhar GR, Vécsei L, Wojszel ZB, Yaman H, Zhang ZG, Cukierman-Yaffe T (2017) The diabetic brain and cognition. J Neural Transm (Vienna) 124, 1431–1454.
    OpenUrl
  63. [63].
    Creese B, Bell E, Johar I, Francis P, Ballard C, Aarsland D (2018) Glucocerebrosidase mutations and neuropsychiatric phenotypes in Parkinson’s disease and Lewy body dementias: Review and meta-analyses. Am J Med Genet B Neuropsychiatr Genet 177, 232–241.
    OpenUrlCrossRef
  64. [64].
    Wajman JR, Mansur LL, Yassuda MS (2018) Lifestyle patterns as a modifiable risk factor for late-life cognitive decline: A narrative review regarding dementia prevention. Curr Aging Sci 11, 90–99.
    OpenUrlCrossRefPubMed
  65. [65].↵
    Jääskeläinen E, Haapea M, Rautio N, Juola P, Penttilä M, Nordström T, Rissanen I, Husa A, Keskinen E, Marttila R, Filatova S, Paaso T-M, Koivukangas J, Moilanen K, Isohanni M, Miettunen J (2015) Twenty years of schizophrenia research in the Northern Finland Birth Cohort 1966: A systematic review. Schizophr Res Treatment 2015, 524875.
    OpenUrl
  66. [66].↵
    Allen GI, Amoroso N, Anghel C, Balagurusamy V, Bare CJ, Beaton D, Bellotti R, Bennett DA, Boehme KL, Boutros PC, Caberlotto L, Caloian C, Campbell F, Chaibub Neto E, Chang Y-C, Chen B, Chen C-Y, Chien T-Y, Clark T, Das S, Davatzikos C, Deng J, Dillenberger D, Dobson RJB, Dong Q, Doshi J, Duma D, Errico R, Erus G, Everett E, Fardo DW, Friend SH, Fröhlich H, Gan J, St George-Hyslop P, Ghosh SS, Glaab E, Green RC, Guan Y, Hong M-Y, Huang C, Hwang J, Ibrahim J, Inglese P, Iyappan A, Jiang Q, Katsumata Y, Kauwe JSK, Klein A, Kong D, Krause R, Lalonde E, Lauria M, Lee E, Lin X, Liu Z, Livingstone J, Logsdon BA, Lovestone S, Ma T-W, Malhotra A, Mangravite LM, Maxwell TJ, Merrill E, Nagorski J, Namasivayam A, Narayan M, Naz M, Newhouse SJ, Norman TC, Nurtdinov RN, Oyang Y-J, Pawitan Y, Peng S, Peters MA, Piccolo SR, Praveen P, Priami C, Sabelnykova VY, Senger P, Shen X, Simmons A, Sotiras A, Stolovitzky G, Tangaro S, Tateo A, Tung Y-A, Tustison NJ, Varol E, Vradenburg G, Weiner MW, Xiao G, Xie L, Xie Y, Xu J, Yang H, Zhan X, Zhou Y, Zhu F, Zhu H, Zhu S, Alzheimer’s Disease Neuroimaging Initiative (2016) Crowdsourced estimation of cognitive decline and resilience in Alzheimer’s disease. Alzheimers Dement 12, 645–653.
    OpenUrlCrossRefPubMed
  67. [67].↵
    Costa IM, Lima FOV, Fernandes LCB, Norrara B, Neta FI, Alves RD, Cavalcanti JRLP, Lucena EES, Cavalcante JS, Rego ACM, Filho IA, Queiroz DB, Freire MAM, Guzen FP (2019) Astragaloside IV supplementation promotes A neuroprotective effect in experimental models of neurological disorders: A systematic review. Curr Neuropharmacol 17, 648–665.
    OpenUrl
  68. [68].↵
    Sami M, Khan H, Nilforooshan R (2015) Late onset mania as an organic syndrome: A review of case reports in the literature. J Affect Disord 188, 226–231.
    OpenUrl
  69. [69].↵
    On the central role of mitochondria dysfunction and oxidative stress in Alzheimers disease.
  70. [70].↵
    Yates LA, Ziser S, Spector A, Orrell M (2016) Cognitive leisure activities and future risk of cognitive impairment and dementia: systematic review and meta-analysis. Int Psychogeriatr 28, 1791–1806.
    OpenUrlCrossRefPubMed
  71. [71].↵
    Mueller C, Soysal P, Rongve A, Isik AT, Thompson T, Maggi S, Smith L, Basso C, Stewart R, Ballard C, O’Brien JT, Aarsland D, Stubbs B, Veronese N (2019) Survival time and differences between dementia with Lewy bodies and Alzheimer’s disease following diagnosis: A meta-analysis of longitudinal studies. Ageing Res Rev 50, 72–80.
    OpenUrlPubMed
  72. [72].↵
    Almeida OP, Hankey GJ, Yeap BB, Paul Chubb SA, Gollege J, Flicker L (2018) Risk of prevalent and incident dementia associated with insulin-like growth factor and insulin-like growth factor-binding protein 3. Mol Psychiatry 23, 1825–1829.
    OpenUrlCrossRef
  73. [73].
    Ettcheto M, Olloquequi J, Sánchez-López E, Busquets O, Cano A, Manzine PR, Beas-Zarate C, Castro-Torres RD, García ML, Bulló M, Auladell C, Folch J, Camins A (2019) Benzodiazepines and related drugs as a risk factor in Alzheimer’s disease dementia. Front Aging Neurosci 11, 344.
    OpenUrl
  74. [74].
    Desai CS, Martin SS, Blumenthal RS (2014) Non-cardiovascular effects associated with statins. BMJ 349, g3743.
    OpenUrlAbstract/FREE Full Text
  75. [75].
    May BH, Feng M, Hyde AJ, Hügel H, Chang S-Y, Dong L, Guo X, Zhang AL, Lu C, Xue CC (2018) Comparisons between traditional medicines and pharmacotherapies for Alzheimer disease: A systematic review and meta-analysis of cognitive outcomes. Int J Geriatr Psychiatry 33, 449–458.
    OpenUrl
  76. [76].
    Danat IM, Clifford A, Partridge M, Zhou W, Bakre AT, Chen A, McFeeters D, Smith T, Wan Y, Copeland J, Anstey KJ, Chen R (2019) Impacts of overweight and obesity in older age on the risk of dementia: A systematic literature review and a meta-analysis. J Alzheimers Dis 70, S87–S99.
    OpenUrl
  77. [77].
    Koch M, Jensen MK (2016) HDL-cholesterol and apolipoproteins in relation to dementia. Curr Opin Lipidol 27, 76–87.
    OpenUrlCrossRef
  78. [78].
    Hargis KE, Blalock EM (2017) Transcriptional signatures of brain aging and Alzheimer’s disease: What are our rodent models telling us? Behav Brain Res 322, 311–328.
    OpenUrl
  79. [79].
    Resolution of inflammation, n YYY 3 fatty acid supplementation and Alzheimer disease: A narrative review.
  80. [80].↵
    Snowden MB, Steinman LE, Bryant LL, Cherrier MM, Greenlund KJ, Leith KH, Levy C, Logsdon RG, Copeland C, Vogel M, Anderson LA, Atkins DC, Bell JF, Fitzpatrick AL (2017) Dementia and co-occurring chronic conditions: a systematic literature review to identify what is known and where are the gaps in the evidence? Int J Geriatr Psychiatry 32, 357–371.
    OpenUrlPubMed
  81. [81].↵
    Kuring JK, Mathias JL, Ward L (2018) Prevalence of depression, anxiety and PTSD in people with dementia: A systematic review and meta-analysis. Neuropsychol Rev 28, 393– 416.
    OpenUrlCrossRef
  82. [82].↵
    Min M, Shi T, Sun C, Liang M, Zhang Y, Tian S, Sun Y (2020) The association between orthostatic hypotension and cognition and stroke: a meta-analysis of prospective cohort studies. Blood Press 29, 3–12.
    OpenUrl
  83. [83].
    Egan KJ, Vesterinen HM, Beglopoulos V, Sena ES, Macleod MR (2016) From a mouse: systematic analysis reveals limitations of experiments testing interventions in Alzheimer’s disease mouse models. Evid Based Preclin Med 3, e00015.
    OpenUrl
  84. [84].
    Goodwill AM, Szoeke C (2017) A systematic review and meta-analysis of the effect of low vitamin D on cognition. J Am Geriatr Soc 65, 2161–2168.
    OpenUrlCrossRefPubMed
  85. [85].↵
    Forbes SC, Holroyd-Leduc JM, Poulin MJ, Hogan DB (2015) Effect of nutrients, dietary supplements and vitamins on cognition: A systematic review and meta-analysis of randomized controlled trials. Can Geriatr J 18, 231–245.
    OpenUrlPubMed
  86. [86].↵
    Chalfont G, Milligan C, Simpson J (2020) A mixed methods systematic review of multimodal non-pharmacological interventions to improve cognition for people with dementia. Dementia 19, 1086–1130.
    OpenUrl
  87. [87].↵
    DeRight J, Jorgensen RS, Cabral MJ (2015) Composite cardiovascular risk scores and neuropsychological functioning: a meta-analytic review. Ann Behav Med 49, 344–357.
    OpenUrl
  88. [88].
    Penninkilampi R, Casey A-N, Singh MF, Brodaty H (2018) The association between social engagement, loneliness, and risk of dementia: A systematic review and meta-analysis. J Alzheimers Dis 66, 1619–1633.
    OpenUrl
  89. [89].
    Ford AH (2016) Preventing delirium in dementia: Managing risk factors. Maturitas 92, 35– 40.
    OpenUrl
  90. [90].
    O’Brien J, Jackson JW, Grodstein F, Blacker D, Weuve J (2014) Postmenopausal hormone therapy is not associated with risk of all-cause dementia and Alzheimer’s disease. Epidemiol Rev 36, 83–103.
    OpenUrlCrossRefPubMed
  91. [91].↵
    Ma J, Zhang W, Wang H-F, Wang Z-X, Jiang T, Tan M-S, Yu J-T, Tan L (2016) Peripheral blood adipokines and insulin levels in patients with Alzheimer’s disease: A replication study and meta-analysis. Curr Alzheimer Res 13, 223–233.
    OpenUrlCrossRefPubMed
  92. [92].
    Weiland A, Wang Y, Wu W, Lan X, Han X, Li Q, Wang J (2019) Ferroptosis and its role in diverse brain diseases. Mol Neurobiol 56, 4880–4893.
    OpenUrlCrossRef
  93. [93].
    Mitochondria-And oxidative stress-targeting substances in cognitive decline-related disorders-And molecular mechanisms to clinical evidence.
  94. [94].
    Lucchetta RC, da Mata BPM, Mastroianni P de C (2018) Association between development of dementia and use of benzodiazepines: A systematic review and meta-analysis. Pharmacotherapy 38, 1010–1020.
    OpenUrl
  95. [95].↵
    Ford AH, Almeida OP (2015) Pharmacological interventions for preventing delirium in the elderly. Maturitas 81, 287–292.
    OpenUrlCrossRefPubMed
  96. [96].↵
    Can Yoga-Based Diabetes Management Studies Facilitate Integrative Medicine in India Current Status and Future Directions.
  97. [97].↵
    Zhao E, Lowres N, Woolaston A, Naismith SL, Gallagher R (2020) Prevalence and patterns of cognitive impairment in acute coronary syndrome patients: A systematic review. Eur J Prev Cardiol 27, 284–293.
    OpenUrl
  98. [98].↵
    Hendriks LEL, Schoenmaekers J, Zindler JD, Eekers DBP, Hoeben A, De Ruysscher DKM, Dingemans A-MC (2015) Safety of cranial radiotherapy concurrent with tyrosine kinase inhibitors in non-small cell lung cancer patients: A systematic review. Cancer Treat Rev 41, 634–645.
    OpenUrl
  99. [99].↵
    Howes LG (2014) Cardiovascular effects of drugs used to treat Alzheimer’s disease. Drug Saf 37, 391–395.
    OpenUrlCrossRefPubMedWeb of Science
  100. [100].↵
    Jensen LE, Padilla R (2011) Effectiveness of interventions to prevent falls in people with Alzheimer’s disease and related dementias. Am J Occup Ther 65, 532–540.
    OpenUrlCrossRefPubMed
  101. [101].
    Deví Bastida J, Genescà Pujol J, Valle Vives S, Jofre Font S, Fetscher Eickhoff A, Arroyo Cardona E (2019) Disorder of the personality: a possible factor of risk for the dementia. Actas Esp Psiquiatr 47, 61–69.
    OpenUrl
  102. [102].
    Wylęgała A (2018) Principles of OCTA and applications in clinical neurology. Curr Neurol Neurosci Rep 18, 96.
    OpenUrl
  103. [103].
    van den Berg E, Geerlings MI, Biessels GJ, Nederkoorn PJ, Kloppenborg RP (2018) White matter hyperintensities and cognition in mild cognitive impairment and Alzheimer’s disease: A domain-specific meta-analysis. J Alzheimers Dis 63, 515–527.
    OpenUrl
  104. [104].
    Gagnon M, Barrette J, Macoir J (2018) Language disorders in Huntington disease: A systematic literature review. Cogn Behav Neurol 31, 179–192.
    OpenUrlCrossRef
  105. [105].↵
    Dwyer R, Stoelwinder J, Gabbe B, Lowthian J (2015) Unplanned transfer to emergency departments for frail elderly residents of aged care facilities: A review of patient and organizational factors. J Am Med Dir Assoc 16, 551–562.
    OpenUrlPubMed
  106. [106].↵
    Pedersen GA, Zajkowska Z, Kieling C, Gautam K, Mondelli V, Fisher HL, Swartz JR, Adewuya A, Karmacharya R, Kohrt BA (2019) Protocol for a systematic review of the development of depression among adolescents and young adults: psychological, biological, and contextual perspectives around the world. Syst Rev 8, 179.
    OpenUrlPubMed
  107. [107].↵
    Effects of vasodilatingmedications on cerebral Haemodynamics in health and disease: Systematic Review andmeta-analysis.
  108. [108].
    Rochoy M, Rivas V, Chazard E, Decarpentry E, Saudemont G, Hazard P-A, Puisieux F, Gautier S, Bordet R (2019) Factors associated with Alzheimer’s disease: An overview of reviews. J Prev Alzheimers Dis 6, 121–134.
    OpenUrl
  109. [109].↵
    Rensma SP, van Sloten TT, Launer LJ, Stehouwer CDA (2018) Cerebral small vessel disease and risk of incident stroke, dementia and depression, and all-cause mortality: A systematic review and meta-analysis. Neurosci Biobehav Rev 90, 164–173.
    OpenUrlCrossRefPubMed
  110. [110].↵
    Franks PW, Atabaki-Pasdar N (2017) Causal inference in obesity research. J Intern Med 281, 222–232.
    OpenUrlPubMed
  111. [111].
    Yuan H, Du L, Ge P, Wang X, Xia Q (2018) Association of microtubule-associated protein tau gene polymorphisms with the risk of sporadic Alzheimer’s disease: a meta-analysis. Int J Neurosci 128, 577–585.
    OpenUrl
  112. [112].
    Schrag M, Mueller C, Zabel M, Crofton A, Kirsch WM, Ghribi O, Squitti R, Perry G (2013) Oxidative stress in blood in Alzheimer’s disease and mild cognitive impairment: a meta-analysis. Neurobiol Dis 59, 100–110.
    OpenUrlCrossRefPubMed
  113. [113].
    Vreeman RC, Scanlon ML, McHenry MS, Nyandiko WM (2015) The physical and psychological effects of HIV infection and its treatment on perinatally HIV-infected children. J Int AIDS Soc 18, 20258.
    OpenUrl
  114. [114].↵
    Ghafar MZAA, Miptah HN, O’Caoimh R (2019) Cognitive screening instruments to identify vascular cognitive impairment: A systematic review. Int J Geriatr Psychiatry 34, 1114–1127.
    OpenUrl
  115. [115].
    Donovan J, Cancelliere C, Cassidy JD (2014) Summary of the findings of the International Collaboration on Mild Traumatic Brain Injury Prognosis. Chiropr Man Therap 22, 38.
    OpenUrl
  116. [116].↵
    Nordestgaard LT, Tybjærg-Hansen A, Rasmussen KL, Nordestgaard BG, Frikke-Schmidt R (2018) Genetic variation in clusterin and risk of dementia and ischemic vascular disease in the general population: cohort studies and meta-analyses of 362,338 individuals. BMC Med 16, 39.
    OpenUrl
  117. [117].↵
    Canevelli M, Bruno G, Vico C, Zaccaria V, Lacorte E, Iavicoli I, Vanacore N, Cesari M (2018) Socioeconomic disparities in clinical trials on Alzheimer’s disease: a systematic review. Eur J Neurol 25, 626–e43.
    OpenUrl
  118. [118].↵
    Bloomfield HE, Koeller E, Greer N, MacDonald R, Kane R, Wilt TJ (2016) Effects on health outcomes of a Mediterranean diet with no restriction on fat intake: A systematic review and meta-analysis. Ann Intern Med 165, 491–500.
    OpenUrlCrossRefPubMed
  119. [119].
    Associations Between H Folic Acid, Vitamin B12 and Alzheimer’s Disease: Insights from Meta-Analyses.
  120. [120].↵
    Ray CA, Ingram V, Cohen-Mansfield J (2015) Systematic review of planned care transitions for persons with dementia. Neurodegener Dis Manag 5, 317–331.
    OpenUrlPubMed
  121. [121].↵
    Weston PSJ, Simpson IJA, Ryan NS, Ourselin S, Fox NC (2015) Diffusion imaging changes in grey matter in Alzheimer’s disease: a potential marker of early neurodegeneration. Alzheimers Res Ther 7, 47.
    OpenUrlCrossRefPubMed
  122. [122].↵
    De Guio F, Duering M, Fazekas F, De Leeuw F-E, Greenberg SM, Pantoni L, Aghetti A, Smith EE, Wardlaw J, Jouvent E (2020) Brain atrophy in cerebral small vessel diseases: Extent, consequences, technical limitations and perspectives: The HARNESS initiative. J Cereb Blood Flow Metab 40, 231–245.
    OpenUrlCrossRefPubMed
  123. [123].↵
    de Wilde A, van Buchem MM, Otten RHJ, Bouwman F, Stephens A, Barkhof F, Scheltens P, van der Flier WM (2018) Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review. Alzheimers Res Ther 10, 72.
    OpenUrl
  124. [124].↵
    Navipour E, Neamatshahi M, Barabadi Z, Neamatshahi M, Keykhosravi A (2019) Epidemiology and risk factors of Alzheimer’s disease in Iran: A systematic review. Iran J Public Health 48, 2133–2139.
    OpenUrl
  125. [125].
    Egan KJ, Pinto-Bruno ÁC, Bighelli I, Berg-Weger M, van Straten A, Albanese E, Pot A-M (2018) Online training and support programs designed to improve mental health and reduce burden among caregivers of people with dementia: A systematic review. J Am Med Dir Assoc 19, 200–206.e1.
    OpenUrlPubMed
  126. [126].
    Wang X-F, Lin X, Li D-Y, Zhou R, Greenbaum J, Chen Y-C, Zeng C-P, Peng L-P, Wu K- H, Ao Z-X, Lu J-M, Guo Y-F, Shen J, Deng H-W (2017) Linking Alzheimer’s disease and type 2 diabetes: Novel shared susceptibility genes detected by cFDR approach. J Neurol Sci 380, 262–272.
    OpenUrl
  127. [127].
    Siklos M, BenAissa M, Thatcher GRJ (2015) Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors. Acta Pharm Sin B 5, 506–519.
    OpenUrl
  128. [128].↵
    Mohammad S, Nguyen H, Nguyen M, Abdel-Rasoul M, Nguyen V, Nguyen CD, Nguyen KT, Li L, Kitzmiller JP (2019) Pleiotropic effects of statins: Untapped potential for statin pharmacotherapy. Curr Vasc Pharmacol 17, 239–261.
    OpenUrlCrossRefPubMed
  129. [129].
    Li F-J, Shen L, Ji H-F (2012) Dietary intakes of vitamin E, vitamin C, and β-carotene and risk of Alzheimer’s disease: a meta-analysis. J Alzheimers Dis 31, 253–258.
    OpenUrl
  130. [130].
    Karlsson WK, Sørensen CG, Kruuse C (2017) l-arginine and l-NMMA for assessing cerebral endothelial dysfunction in ischaemic cerebrovascular disease: A systematic review. Clin Exp Pharmacol Physiol 44, 13–20.
    OpenUrl
  131. [131].
    Dolan C, Glynn R, Lawlor B (2020) A systematic review and Delphi study to ascertain common risk factors for type 2 diabetes mellitus and dementia and brain-related complications of diabetes in adults. Can J Diabetes 44, 628–635.
    OpenUrl
  132. [132].
    Vlaeyen E, Coussement J, Leysens G, Van der Elst E, Delbaere K, Cambier D, Denhaerynck K, Goemaere S, Wertelaers A, Dobbels F, Dejaeger E, Milisen K, Center of Expertise for Fall and Fracture Prevention Flanders (2015) Characteristics and effectiveness of fall prevention programs in nursing homes: a systematic review and meta-analysis of randomized controlled trials. J Am Geriatr Soc 63, 211–221.
    OpenUrlCrossRefPubMed
  133. [133].
    Solanki RK, Dubey V, Munshi D (2009) Neurocognitive impairment and comorbid depression in patients of diabetes mellitus. Int J Diabetes Dev Ctries 29, 133–138.
    OpenUrlPubMed
  134. [134].
    Polyakova M, Sonnabend N, Sander C, Mergl R, Schroeter ML, Schroeder J, Schönknecht P (2014) Prevalence of minor depression in elderly persons with and without mild cognitive impairment: a systematic review. J Affect Disord 152–154, 28–38.
  135. [135].
    El Kadmiri N, Said N, Slassi I, El Moutawakil B, Nadifi S (2018) Biomarkers for Alzheimer disease: Classical and novel candidates’ review. Neuroscience 370, 181–190.
    OpenUrl
  136. [136].
    Ning M, Lo EH, Ning P-C, Xu S-Y, McMullin D, Demirjian Z, Inglessis I, Dec GW, Palacios I, Buonanno FS (2013) The brain’s heart – therapeutic opportunities for patent foramen ovale (PFO) and neurovascular disease. Pharmacol Ther 139, 111–123.
    OpenUrlCrossRefPubMed
  137. [137].↵
    Yaffe K (2018) Modifiable risk factors and prevention of dementia: What is the latest evidence? JAMA Intern Med 178, 281–282.
    OpenUrl
  138. [138].↵
    Resciniti NV, Tang W, Tabassum M, Pearson JL, Spencer SM, Lohman MC, Ehlers DK, Al-Hasan D, Miller MC, Teixeira A, Friedman DB (2020) Knowledge evaluation instruments for dementia caregiver education programs: A scoping review. Geriatr Gerontol Int 20, 397–413.
    OpenUrl
  139. [139].↵
    Islam MM, Poly TN, Walther BA, Dubey NK, Anggraini Ningrum DN, Shabbir S-A, Jack Li Y-C (2018) Adverse outcomes of long-term use of proton pump inhibitors: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 30, 1395–1405.
    OpenUrl
  140. [140].
    Cancelliere C, Cassidy JD, Li A, Donovan J, Côté P, Hincapié CA (2014) Systematic search and review procedures: results of the International Collaboration on Mild Traumatic Brain Injury Prognosis. Arch Phys Med Rehabil 95, S101–31.
    OpenUrl
  141. [141].
    Sarker MR, Franks SF (2018) Efficacy of curcumin for age-associated cognitive decline: a narrative review of preclinical and clinical studies. GeroScience 40, 73–95.
    OpenUrl
  142. [142].
    Loures C de MG, Duarte RCF, Silva MVF, Cicarini WB, de Souza LC, Caramelli P, Borges KBG, Carvalho M das G (2019) Hemostatic abnormalities in dementia: A systematic review and meta-analysis. Semin Thromb Hemost 45, 514–522.
    OpenUrlCrossRef
  143. [143].
    Bennett JM, Chekaluk E, Batchelor J (2016) Cognitive tests and determining fitness to drive in dementia: A systematic review. J Am Geriatr Soc 64, 1904–1917.
    OpenUrlCrossRefPubMed
  144. [144].↵
    Benny A, Thomas J (2019) Essential oils as treatment strategy for Alzheimer’s disease: Current and future perspectives. Planta Med 85, 239–248.
    OpenUrl
  145. [145].↵
    Klimek L, Kündig T, Kramer MF, Guethoff S, Jensen-Jarolim E, Schmidt-Weber CB, Palomares O, Mohsen MO, Jakob T, Bachmann M (2018) Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases. Allergo J Int 27, 245–255.
    OpenUrl
  146. [146].↵
    Smith TO, Cooper A, Peryer G, Griffiths R, Fox C, Cross J (2017) Factors predicting incidence of post-operative delirium in older people following hip fracture surgery: a systematic review and meta-analysis. Int J Geriatr Psychiatry 32, 386–396.
    OpenUrl
  147. [147].↵
    Chan JYC, Yiu KKL, Kwok TCY, Wong SYS, Tsoi KKF (2019) Depression and antidepressants as potential risk factors in dementia: A systematic review and meta-analysis of 18 longitudinal studies. J Am Med Dir Assoc 20, 279–286.e1.
    OpenUrlCrossRef
  148. [148].↵
    Cao G-Y, Li M, Han L, Tayie F, Yao S-S, Huang Z, Ai P, Liu Y-Z, Hu Y-H, Xu B (2019) Dietary fat intake and cognitive function among older populations: A systematic review and meta-analysis. J Prev Alzheimers Dis 6, 204–211.
    OpenUrl
  149. [149].↵
    Mortamais M, Ash JA, Harrison J, Kaye J, Kramer J, Randolph C, Pose C, Albala B, Ropacki M, Ritchie CW, Ritchie K (2017) Detecting cognitive changes in preclinical Alzheimer’s disease: A review of its feasibility. Alzheimers Dement 13, 468–492.
    OpenUrl
  150. [150].↵
    Shepherd H, Livingston G, Chan J, Sommerlad A (2019) Hospitalisation rates and predictors in people with dementia: a systematic review and meta-analysis. BMC Med 17, 130.
    OpenUrlPubMed
  151. [151].↵
    Quantifying observational evidence for risk of dementia following androgen deprivation therapy for prostate cancer: an updated systematic review and m… Show all.
  152. [152].↵
    Perry DC, Sturm VE, Peterson MJ, Pieper CF, Bullock T, Boeve BF, Miller BL, Guskiewicz KM, Berger MS, Kramer JH, Welsh-Bohmer KA (2016) Association of traumatic brain injury with subsequent neurological and psychiatric disease: a meta-analysis. J Neurosurg 124, 511–526.
    OpenUrlCrossRefPubMed
  153. [153].↵
    Stephan BCM, Birdi R, Tang EYH, Cosco TD, Donini LM, Licher S, Ikram MA, Siervo M, Robinson L (2018) Secular trends in dementia prevalence and incidence worldwide: A systematic review. J Alzheimers Dis 66, 653–680.
    OpenUrl
  154. [154].
    Mokhar A, Topp J, Härter M, Schulz H, Kuhn S, Verthein U, Dirmaier J (2018) Patient-centered care interventions to reduce the inappropriate prescription and use of benzodiazepines and z-drugs: a systematic review. PeerJ 6, e5535.
    OpenUrlCrossRefPubMed
  155. [155].↵
    Becker E, Orellana Rios CL, Lahmann C, Rücker G, Bauer J, Boeker M (2018) Anxiety as a risk factor of Alzheimer’s disease and vascular dementia. Br J Psychiatry 213, 654–660.
    OpenUrl
  156. [156].
    Kivimäki M, Singh-Manoux A, Pentti J, Sabia S, Nyberg ST, Alfredsson L, Goldberg M, Knutsson A, Koskenvuo M, Koskinen A, Kouvonen A, Nordin M, Oksanen T, Strandberg T, Suominen SB, Theorell T, Vahtera J, Väänänen A, Virtanen M, Westerholm P, Westerlund H, Zins M, Seshadri S, Batty GD, Sipilä PN, Shipley MJ, Lindbohm JV, Ferrie JE, Jokela M, IPD-Work consortium (2019) Physical inactivity, cardiometabolic disease, and risk of dementia: an individual-participant meta-analysis. BMJ 365, l1495.
    OpenUrlAbstract/FREE Full Text
  157. [157].
    Pal K, Mukadam N, Petersen I, Cooper C (2018) Mild cognitive impairment and progression to dementia in people with diabetes, prediabetes and metabolic syndrome: a systematic review and meta-analysis. Soc Psychiatry Psychiatr Epidemiol 53, 1149–1160.
    OpenUrlCrossRef
  158. [158].↵
    Meyer C, Hill S, Dow B, Synnot A, Hill K (2015) Translating falls prevention knowledge to community-dwelling older PLWD: A mixed-method systematic review. Gerontologist 55, 560–574.
    OpenUrlCrossRefPubMed
  159. [159].
    Stefanidis KB, Askew CD, Greaves K, Summers MJ (2018) The effect of non-stroke cardiovascular disease states on risk for cognitive decline and dementia: A systematic and meta-analytic review. Neuropsychol Rev 28, 1–15.
    OpenUrlCrossRefPubMed
  160. [160].↵
    Rose S, Niyazov DM, Rossignol DA, Goldenthal M, Kahler SG, Frye RE (2018) Clinical and molecular characteristics of mitochondrial dysfunction in autism spectrum disorder. Mol Diagn Ther 22, 571–593.
    OpenUrl
  161. [161].↵
    Oudman E, Wijnia JW, van Dam M, Biter LU, Postma A (2018) Preventing Wernicke encephalopathy after bariatric surgery. Obes Surg 28, 2060–2068.
    OpenUrlPubMed
  162. [162].↵
    Debette S, Markus HS (2010) The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 341, c3666.
    OpenUrlAbstract/FREE Full Text
  163. [163].↵
    Surendranathan A, Rowe JB, O’Brien JT (2015) Neuroinflammation in Lewy body dementia. Parkinsonism Relat Disord 21, 1398–1406.
    OpenUrlPubMed
  164. [164].↵
    Continuing education for the prevention of mild cognitive impairment and Alzheimer’s-type dementia: a systematic review and overview of systematic rev… Show all.
  165. [165].
    Canevelli M, Bruno G, Grande G, Quarata F, Raganato R, Remiddi F, Valletta M, Zaccaria V, Vanacore N, Cesari M (2019) Race reporting and disparities in clinical trials on Alzheimer’s disease: A systematic review. Neurosci Biobehav Rev 101, 122–128.
    OpenUrl
  166. [166].
    Cai B, Zhang Y, Wang Z, Xu D, Jia Y, Guan Y, Liao A, Liu G, Chun C, Li J (2020) Therapeutic potential of diosgenin and its major derivatives against neurological diseases: Recent advances. Oxid Med Cell Longev 2020, 3153082.
    OpenUrl
  167. [167].↵
    Zeng D, Jiang C, Su C, Tan Y, Wu J (2019) Anticoagulation in atrial fibrillation and cognitive decline: A systematic review and meta-analysis. Medicine (Baltimore) 98, e14499.
    OpenUrlCrossRefPubMed
  168. [168].↵
    Chai B, Gao F, Wu R, Dong T, Gu C, Lin Q, Zhang Y (2019) Vitamin D deficiency as a risk factor for dementia and Alzheimer’s disease: an updated meta-analysis. BMC Neurol 19, 284.
    OpenUrl
  169. [169].
    Protocol for a systematic review of the development of depression among adolescents and young adults: Psychological, biological, and contextual perspe… Show all.
  170. [170].↵
    Hussenoeder FS, Riedel-Heller SG (2018) Primary prevention of dementia: from modifiable risk factors to a public brain health agenda? Soc Psychiatry Psychiatr Epidemiol 53, 1289–1301.
    OpenUrlCrossRef
  171. [171].
    Valencia WM, Botros D, Vera-Nunez M, Dang S (2018) Diabetes treatment in the elderly: Incorporating geriatrics, technology, and functional medicine. Curr Diab Rep 18, 95.
    OpenUrl
  172. [172].↵
    An R, Nickols-Richardson SM, Khan N, Liu J, Liu R, Clarke C (2019) Impact of beef and beef product intake on cognition in children and young adults: A systematic review. Nutrients 11, 1797.
    OpenUrl
  173. [173].
    Loperto I, Simonetti A, Nardone A, Triassi M (2019) Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidence. Hum Vaccin Immunother 15, 1035–1047.
    OpenUrl
  174. [174].
    Backhouse T, Camino J, Mioshi E (2018) What do we know about behavioral crises in dementia? A systematic review. J Alzheimers Dis 62, 99–113.
    OpenUrl
  175. [175].
    Möllers T, Stocker H, Wei W, Perna L, Brenner H (2019) Length of hospital stay and dementia: A systematic review of observational studies. Int J Geriatr Psychiatry 34, 8–21.
    OpenUrlPubMed
  176. [176].
    Moore DC, Keegan TJ, Dunleavy L, Froggatt K (2019) Factors associated with length of stay in care homes: a systematic review of international literature. Syst Rev 8, 56.
    OpenUrl
  177. [177].
    Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C (2014) Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. Lancet Neurol 13, 788–794.
    OpenUrlCrossRefPubMedWeb of Science
  178. [178].↵
    Veronese N, Zurlo A, Solmi M, Luchini C, Trevisan C, Bano G, Manzato E, Sergi G, Rylander R (2016) Magnesium status in Alzheimer’s disease: A systematic review. Am J Alzheimers Dis Other Demen 31, 208–213.
    OpenUrlCrossRefPubMed
  179. [179].
    Bayani M, Riahi SM, Bazrafshan N, Ray Gamble H, Rostami A (2019) Toxoplasma gondii infection and risk of Parkinson and Alzheimer diseases: A systematic review and meta-analysis on observational studies. Acta Trop 196, 165–171.
    OpenUrl
  180. [180].↵
    Frieser MJ, Wilson S, Vrieze S (2018) Behavioral impact of return of genetic test results for complex disease: Systematic review and meta-analysis. Health Psychol 37, 1134–1144.
    OpenUrlCrossRef
  181. [181].↵
    Molino S, Dossena M, Buonocore D, Ferrari F, Venturini L, Ricevuti G, Verri M (2016) Polyphenols in dementia: From molecular basis to clinical trials. Life Sci 161, 69–77.
    OpenUrl
  182. [182].↵
    Rozas NS, Sadowsky JM, Jeter CB (2017) Strategies to improve dental health in elderly patients with cognitive impairment: A systematic review. J Am Dent Assoc 148, 236–245.e3.
    OpenUrlPubMed
  183. [183].↵
    Falck RS, Davis JC, Liu-Ambrose T (2017) What is the association between sedentary behaviour and cognitive function? A systematic review. Br J Sports Med 51, 800–811.
    OpenUrlAbstract/FREE Full Text
  184. [184].↵
    Derbyshire E (2018) Brain health across the lifespan: A systematic review on the role of omega-3 fatty acid supplements. Nutrients 10,.
  185. [185].
    Fink HA, Jutkowitz E, McCarten JR, Hemmy LS, Butler M, Davila H, Ratner E, Calvert C, Barclay TR, Brasure M, Nelson VA, Kane RL (2018) Pharmacologic interventions to prevent cognitive decline, mild cognitive impairment, and clinical Alzheimer-type dementia: A systematic review. Ann Intern Med 168, 39–51.
    OpenUrlCrossRefPubMed
  186. [186].
    Martinez F, Tobar C, Hill N (2015) Preventing delirium: should non-pharmacological, multicomponent interventions be used? A systematic review and meta-analysis of the literature. Age Ageing 44, 196–204.
    OpenUrlCrossRefPubMed
  187. [187].↵
    Vagelatos NT, Eslick GD (2013) Type 2 diabetes as a risk factor for Alzheimer’s disease: the confounders, interactions, and neuropathology associated with this relationship. Epidemiol Rev 35, 152–160.
    OpenUrlCrossRefPubMed
  188. [188].↵
    Shams S, Wahlund L-O (2016) Cerebral microbleeds as a biomarker in Alzheimer’s disease? A review in the field. Biomark Med 10, 9–18.
    OpenUrl
  189. [189].↵
    Sibbett RA, Russ TC, Deary IJ, Starr JM (2017) Dementia ascertainment using existing data in UK longitudinal and cohort studies: a systematic review of methodology. BMC Psychiatry 17, 239.
    OpenUrlCrossRefPubMed
  190. [190].↵
    Zingler G, Hermann B, Fischer T, Herdegen T (2016) Cardiovascular adverse events by non-steroidal anti-inflammatory drugs: when the benefits outweigh the risks. Expert Rev Clin Pharmacol 9, 1479–1492.
    OpenUrl
  191. [191].↵
    Strimbu K, Tavel JA (2010) What are biomarkers? Curr Opin HIV AIDS 5, 463–466.
    OpenUrlCrossRefPubMedWeb of Science
  192. [192].↵
    Lee Y, Back JH, Kim J, Kim S-H, Na DL, Cheong H-K, Hong CH, Kim YG (2010) Systematic review of health behavioral risks and cognitive health in older adults. Int Psychogeriatr 22, 174–187.
    OpenUrlCrossRefPubMed
  193. [193].
    Sood R, Faubion SS, Kuhle CL, Thielen JM, Shuster LT (2014) Prescribing menopausal hormone therapy: an evidence-based approach. Int J Womens Health 6, 47–57.
    OpenUrlPubMed
  194. [194].
    Chokesuwattanaskul A, Lertjitbanjong P, Thongprayoon C, Bathini T, Sharma K, Mao MA, Cheungpasitporn W, Chokesuwattanaskul R (2020) Impact of obstructive sleep apnea on silent cerebral small vessel disease: a systematic review and meta-analysis. Sleep Med 68, 80–88.
    OpenUrlPubMed
  195. [195].
    Shen Z, Ruan Q, Yu Z, Sun Z (2017) Chronic kidney disease-related physical frailty and cognitive impairment: a systemic review. Geriatr Gerontol Int 17, 529–544.
    OpenUrl
  196. [196].↵
    Martins YA, Tsuchida CJ, Antoniassi P, Demarchi IG (2017) Efficacy and safety of the immunization with DNA for Alzheimer’s disease in animal models: A systematic review from literature. J Alzheimers Dis Rep 1, 195–217.
    OpenUrl
  197. [197].
    Low L-F, Yap MHW, Brodaty H (2010) Will testing for apolipoprotein E assist in tailoring dementia risk reduction? A review. Neurosci Biobehav Rev 34, 408–437.
    OpenUrlCrossRefPubMed
  198. [198].
    Valenti R, Pantoni L, Markus HS (2014) Treatment of vascular risk factors in patients with a diagnosis of Alzheimer’s disease: a systematic review. BMC Med 12, 160.
    OpenUrlCrossRefPubMed
  199. [199].
    Depressive Symptoms in Mild Cognitive Impairment and the Risk of Dementia: A Systematic Review and Comparative Meta-Analysis of Clinical and Community… Show all.
  200. [200].↵
    Chee JN, Rapoport MJ, Molnar F, Herrmann N, O’Neill D, Marottoli R, Mitchell S, Tant M, Dow J, Ayotte D, Lanctôt KL, McFadden R, Taylor J-P, Donaghy PC, Olsen K, Classen S, Elzohairy Y, Carr DB (2017) Update on the risk of motor vehicle collision or driving impairment with dementia: A collaborative international systematic review and meta-analysis. Am J Geriatr Psychiatry 25, 1376–1390.
    OpenUrl
  201. [201].
    Joska JA, Gouse H, Paul RH, Stein DJ, Flisher AJ (2010) Does highly active antiretroviral therapy improve neurocognitive function? A systematic review. J Neurovirol 16, 101–114.
    OpenUrlCrossRefPubMedWeb of Science
  202. [202].
    Llibre Rodríguez J de J (2013) Aging and dementia: Implications for Cuba’s research community, public health and society. MEDICC Rev 15, 54–59.
    OpenUrl
  203. [203].↵
    Parial LL, Lam SC, Ho JYS, Suen LKP, Leung AYM (2021) Public knowledge of the influence of modifiable cardiovascular risk factors on dementia: a systematic literature review and meta-analysis. Aging Ment Health 25, 1395–1409.
    OpenUrl
  204. [204].↵
    Buswell M, Goodman C, Roe B, Russell B, Norton C, Harwood R, Fader M, Harari D, Drennan VM, Malone JR, Madden M, Bunn F (2017) What works to improve and manage fecal incontinence in care home residents living with dementia? A realist synthesis of the evidence. J Am Med Dir Assoc 18, 752–760.e1.
    OpenUrl
  205. [205].
    Phelan EA, Debnam KJ, Anderson LA, Owens SB (2015) A systematic review of intervention studies to prevent hospitalizations of community-dwelling older adults with dementia. Med Care 53, 207–213.
    OpenUrlCrossRefPubMed
  206. [206].
    Etgen T, Sander D, Bickel H, Förstl H (2011) Mild cognitive impairment and dementia: the importance of modifiable risk factors. Dtsch Arztebl Int 108, 743–750.
    OpenUrlPubMed
  207. [207].
    Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D (2019) Pharmacological management of osteoporosis in postmenopausal women: An endocrine society* clinical practice guideline. J Clin Endocrinol Metab 104, 1595–1622.
    OpenUrlCrossRefPubMed
  208. [208].
    Zhang Y, Zhang J, Tian C, Xiao Y, Li X, He C, Huang J, Fan H (2011) The –1082G/A polymorphism in IL-10 gene is associated with risk of Alzheimer’s disease: a meta-analysis. J Neurol Sci 303, 133–138.
    OpenUrlCrossRefPubMed
  209. [209].
    Cannistraro RJ, Badi M, Eidelman BH, Dickson DW, Middlebrooks EH, Meschia JF (2019) CNS small vessel disease: A clinical review. Neurology 92, 1146–1156.
    OpenUrlCrossRefPubMed
  210. [210].↵
    Topiwala H, Terrera GM, Stirland L, Saunderson K, Russ TC, Dozier MF, Ritchie CW (2018) Lifestyle and neurodegeneration in midlife as expressed on functional magnetic resonance imaging: A systematic review. Alzheimers Dement (N Y) 4, 182–194.
    OpenUrl
  211. [211].↵
    Debette S, Schilling S, Duperron M-G, Larsson SC, Markus HS (2019) Clinical significance of magnetic resonance imaging markers of vascular brain injury: A systematic review and meta-analysis. JAMA Neurol 76, 81–94.
    OpenUrl
  212. [212].↵
    Cao L, Tan L, Wang H-F, Jiang T, Zhu X-C, Yu J-T (2017) Cerebral microinfarcts and dementia: A systematic review and metaanalysis. Curr Alzheimer Res 14, 802–808.
    OpenUrl
  213. [213].↵
    Postoperative delirium after hip surgery is a potential risk factor for incident dementia: A systematic review and meta-analysis of prospective studie… Show all.
  214. [214].
    Rutjes AW, Denton DA, Di Nisio M, Chong L-Y, Abraham RP, Al-Assaf AS, Anderson JL, Malik MA, Vernooij RW, Martínez G, Tabet N, McCleery J (2018) Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life. Cochrane Database Syst Rev 12, CD011906.
    OpenUrlCrossRefPubMed
  215. [215].
    Guerchet M, Aboyans V, Nubukpo P, Lacroix P, Clément J-P, Preux P-M (2011) Ankle-brachial index as a marker of cognitive impairment and dementia in general population. A systematic review. Atherosclerosis 216, 251–257.
    OpenUrlCrossRefPubMed
  216. [216].↵
    Bornstein S, Baker R, Navarro P, Mackey S, Speed D, Sullivan M (2017) Putting research in place: an innovative approach to providing contextualized evidence synthesis for decision makers. Syst Rev 6, 218.
    OpenUrl
  217. [217].↵
    Ligthart SA, Richard E, van Gool WA, Moll van Charante EP (2012) Cardiovascular risk management in community-dwelling elderly: opportunities for prevention. Eur J Prev Cardiol 19, 1365–1372.
    OpenUrlCrossRefPubMed
  218. [218].↵
    Fu H, Xu Z, Zhang X-L, Zheng G-Q (2019) Kaixinsan, a well-known Chinese herbal prescription, for Alzheimer’s disease and depression: A preclinical systematic review. Front Neurosci 13, 1421.
    OpenUrl
  219. [219].↵
    Stanley K, Walker Z (2014) Do patients with young onset Alzheimer’s disease deteriorate faster than those with late onset Alzheimer’s disease? A review of the literature. Int Psychogeriatr 26, 1945–1953.
    OpenUrlCrossRefPubMed
  220. [220].↵
    Cheng H, Wang L, Shi T, Shang Y, Jiang L (2015) Association of insulin degrading enzyme gene polymorphisms with Alzheimer’s disease: a meta-analysis. Int J Neurosci 125, 328–335.
    OpenUrl
  221. [221].
    Witlox J, Eurelings LSM, de Jonghe JFM, Kalisvaart KJ, Eikelenboom P, van Gool WA (2010) Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia: a meta-analysis. JAMA 304, 443–451.
    OpenUrlCrossRefPubMedWeb of Science
  222. [222].↵
    Smith L, Luchini C, Demurtas J, Soysal P, Stubbs B, Hamer M, Nottegar A, Lawlor RT, Lopez-Sanchez GF, Firth J, Koyanagi A, Roberts J, Willeit P, Waldhoer T, Loosemore M, Abbs AD, Johnstone J, Yang L, Veronese N (2019) Telomere length and health outcomes: An umbrella review of systematic reviews and meta-analyses of observational studies. Ageing Res Rev 51, 1–10.
    OpenUrlCrossRefPubMed
  223. [223].↵
    Li M, Wang W, Li Y, Wang L, Shen X, Tang Z (2013) CYP46A1 intron-2T/C polymorphism and Alzheimer’s disease: an updated meta-analysis of 16 studies including 3,960 cases and 3,828 controls. Neurosci Lett 549, 18–23.
    OpenUrl
  224. [224].↵
    Schouler-Ocak M, Kastrup MC, Vaishnav M, Javed A (2020) Mental health of migrants. Indian J Psychiatry 62, 242–246.
    OpenUrl
  225. [225].↵
    Sadaie MR, Farhoudi M, Zamanlu M, Aghamohammadzadeh N, Amouzegar A, Rosenbaum RE, Thomas GA (2018) What does the research say about androgen use and cerebrovascular events? Ther Adv Drug Saf 9, 439–455.
    OpenUrl
  226. [226].↵
    Kim JK, Tabassum N, Uddin MR, Park SU (2016) Ginseng: a miracle sources of herbal and pharmacological uses. Orient Pharm Exp Med 16, 243–250.
    OpenUrl
  227. [227].↵
    Hill KD, Hunter SW, Batchelor FA, Cavalheri V, Burton E (2015) Individualized home-based exercise programs for older people to reduce falls and improve physical performance: A systematic review and meta-analysis. Maturitas 82, 72–84.
    OpenUrlCrossRef
  228. [228].↵
    Jensen JS, Reiter-Theil S, Celio DA, Jakob M, Vach W, Saxer FJ (2019) Handling of informed consent and patient inclusion in research with geriatric trauma patients – a matter of protection or disrespect? Clin Interv Aging 14, 321–334.
    OpenUrl
  229. [229].
    Sánchez-Sánchez ML, García-Vigara A, Hidalgo-Mora JJ, García-Pérez M-Á, Tarín J, Cano A (2020) Mediterranean diet and health: A systematic review of epidemiological studies and intervention trials. Maturitas 136, 25–37.
    OpenUrlCrossRef
  230. [230].↵
    Cass SP (2017) Alzheimer’s disease and exercise: A literature review. Curr Sports Med Rep 16, 19–22.
    OpenUrl
  231. [231].↵
    Yan D, Zhang Y, Liu L, Yan H (2016) Pesticide exposure and risk of Alzheimer’s disease: a systematic review and meta-analysis. Sci Rep 6, 32222.
    OpenUrlPubMed
  232. [232].↵
    de Oliveira Silva F, Ferreira JV, Plácido J, Chagas D, Praxedes J, Guimarães C, Batista LA, Marinho V, Laks J, Deslandes AC (2019) Stages of mild cognitive impairment and Alzheimer’s disease can be differentiated by declines in timed up and go test: A systematic review and meta-analysis. Arch Gerontol Geriatr 85, 103941.
    OpenUrl
  233. [233].
    Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, Boland A, Vronskaya M, van der Lee SJ, Amlie-Wolf A, Bellenguez C, Frizatti A, Chouraki V, Martin ER, Sleegers K, Badarinarayan N, Jakobsdottir J, Hamilton-Nelson KL, Moreno-Grau S, Olaso R, Raybould R, Chen Y, Kuzma AB, Hiltunen M, Morgan T, Ahmad S, Vardarajan BN, Epelbaum J, Hoffmann P, Boada M, Beecham GW, Garnier J-G, Harold D, Fitzpatrick AL, Valladares O, Moutet M-L, Gerrish A, Smith AV, Qu L, Bacq D, Denning N, Jian X, Zhao Y, Del Zompo M, Fox NC, Choi S-H, Mateo I, Hughes JT, Adams HH, Malamon J, Sanchez-Garcia F, Patel Y, Brody JA, Dombroski BA, Naranjo MCD, Daniilidou M, Eiriksdottir G, Mukherjee S, Wallon D, Uphill J, Aspelund T, Cantwell LB, Garzia F, Galimberti D, Hofer E, Butkiewicz M, Fin B, Scarpini E, Sarnowski C, Bush WS, Meslage S, Kornhuber J, White CC, Song Y, Barber RC, Engelborghs S, Sordon S, Voijnovic D, Adams PM, Vandenberghe R, Mayhaus M, Cupples LA, Albert MS, De Deyn PP, Gu W, Himali JJ, Beekly D, Squassina A, Hartmann AM, Orellana A, Blacker D, Rodriguez-Rodriguez E, Lovestone S, Garcia ME, Doody RS, Munoz-Fernadez C, Sussams R, Lin H, Fairchild TJ, Benito YA, Holmes C, Karamujić-Čomić H, Frosch MP, Thonberg H, Maier W, Roshchupkin G, Ghetti B, Giedraitis V, Kawalia A, Li S, Huebinger RM, Kilander L, Moebus S, Hernández I, Kamboh MI, Brundin R, Turton J, Yang Q, Katz MJ, Concari L, Lord J, Beiser AS, Keene CD, Helisalmi S, Kloszewska I, Kukull WA, Koivisto AM, Lynch A, Tarraga L, Larson EB, Haapasalo A, Lawlor B, Mosley TH, Lipton RB, Solfrizzi V, Gill M, Longstreth WT Jr, Montine TJ, Frisardi V, Diez-Fairen M, Rivadeneira F, Petersen RC, Deramecourt V, Alvarez I, Salani F, Ciaramella A, Boerwinkle E, Reiman EM, Fievet N, Rotter JI, Reisch JS, Hanon O, Cupidi C, Uitterlinden AGA, Royall DR, Dufouil C, Maletta RG, de Rojas I, Sano M, Brice A, Cecchetti R, George-Hyslop PS, Ritchie K, Tsolaki M, Tsuang DW, Dubois B, Craig D, Wu C-K, Soininen H, Avramidou D, Albin RL, Fratiglioni L, Germanou A, Apostolova LG, Keller L, Koutroumani M, Arnold SE, Panza F, Gkatzima O, Asthana S, Hannequin D, Whitehead P, Atwood CS, Caffarra P, Hampel H, Quintela I, Carracedo Á, Lannfelt L, Rubinsztein DC, Barnes LL, Pasquier F, Frölich L, Barral S, McGuinness B, Beach TG, Johnston JA, Becker JT, Passmore P, Bigio EH, Schott JM, Bird TD, Warren JD, Boeve BF, Lupton MK, Bowen JD, Proitsi P, Boxer A, Powell JF, Burke JR, Kauwe JSK, Burns JM, Mancuso M, Buxbaum JD, Bonuccelli U, Cairns NJ, McQuillin A, Cao C, Livingston G, Carlson CS, Bass NJ, Carlsson CM, Hardy J, Carney RM, Bras J, Carrasquillo MM, Guerreiro R, Allen M, Chui HC, Fisher E, Masullo C, Crocco EA, DeCarli C, Bisceglio G, Dick M, Ma L, Duara R, Graff-Radford NR, Evans DA, Hodges A, Faber KM, Scherer M, Fallon KB, Riemenschneider M, Fardo DW, Heun R, Farlow MR, Kölsch H, Ferris S, Leber M, Foroud TM, Heuser I, Galasko DR, Giegling I, Gearing M, Hüll M, Geschwind DH, Gilbert JR, Morris J, Green RC, Mayo K, Growdon JH, Feulner T, Hamilton RL, Harrell LE, Drichel D, Honig LS, Cushion TD, Huentelman MJ, Hollingworth P, Hulette CM, Hyman BT, Marshall R, Jarvik GP, Meggy A, Abner E, Menzies GE, Jin L-W, Leonenko G, Real LM, Jun GR, Baldwin CT, Grozeva D, Karydas A, Russo G, Kaye JA, Kim R, Jessen F, Kowall NW, Vellas B, Kramer JH, Vardy E, LaFerla FM, Jöckel K-H, Lah JJ, Dichgans M, Leverenz JB, Mann D, Levey AI, Pickering-Brown S, Lieberman AP, Klopp N, Lunetta KL, Wichmann H-E, Lyketsos CG, Morgan K, Marson DC, Brown K, Martiniuk F, Medway C, Mash DC, Nöthen MM, Masliah E, Hooper NM, McCormick WC, Daniele A, McCurry SM, Bayer A, McDavid AN, Gallacher J, McKee AC, van den Bussche H, Mesulam M, Brayne C, Miller BL, Riedel-Heller S, Miller CA, Miller JW, Al-Chalabi A, Morris JC, Shaw CE, Myers AJ, Wiltfang J, O’Bryant S, Olichney JM, Alvarez V, Parisi JE, Singleton AB, Paulson HL, Collinge J, Perry WR, Mead S, Peskind E, Cribbs DH, Rossor M, Pierce A, Ryan NS, Poon WW, Nacmias B, Potter H, Sorbi S, Quinn JF, Sacchinelli E, Raj A, Spalletta G, Raskind M, Caltagirone C, Bossù P, Orfei MD, Reisberg B, Clarke R, Reitz C, Smith AD, Ringman JM, Warden D, Roberson ED, Wilcock G, Rogaeva E, Bruni AC, Rosen HJ, Gallo M, Rosenberg RN, Ben-Shlomo Y, Sager MA, Mecocci P, Saykin AJ, Pastor P, Cuccaro ML, Vance JM, Schneider JA, Schneider LS, Slifer S, Seeley WW, Smith AG, Sonnen JA, Spina S, Stern RA, Swerdlow RH, Tang M, Tanzi RE, Trojanowski JQ, Troncoso JC, Van Deerlin VM, Van Eldik LJ, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Wilhelmsen KC, Williamson J, Wingo TS, Woltjer RL, Wright CB, Yu C-E, Yu L, Saba Y, Alzheimer Disease Genetics Consortium (ADGC), European Alzheimer’s Disease Initiative (EADI), Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE), Genetic and Environmental Risk in AD/Defining Genetic, Polygenic and Environmental Risk for Alzheimer’s Disease Consortium (GERAD/PERADES), Pilotto A, Bullido MJ, Peters O, Crane PK, Bennett D, Bosco P, Coto E, Boccardi V, De Jager PL, Lleo A, Warner N, Lopez OL, Ingelsson M, Deloukas P, Cruchaga C, Graff C, Gwilliam R, Fornage M, Goate AM, Sanchez-Juan P, Kehoe PG, Amin N, Ertekin-Taner N, Berr C, Debette S, Love S, Launer LJ, Younkin SG, Dartigues J-F, Corcoran C, Ikram MA, Dickson DW, Nicolas G, Campion D, Tschanz J, Schmidt H, Hakonarson H, Clarimon J, Munger R, Schmidt R, Farrer LA, Van Broeckhoven C, O’Donovan MC, DeStefano AL, Jones L, Haines JL, Deleuze J-F, Owen MJ, Gudnason V, Mayeux R, Escott-Price V, Psaty BM, Ramirez A, Wang L-S, Ruiz A, van Duijn CM, Holmans PA, Seshadri S, Williams J, Amouyel P, Schellenberg GD, Lambert J-C, Pericak-Vance MA (2019) Author Correction: Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat Genet 51, 1423–1424.
    OpenUrlCrossRef
  234. [234].
    Cicala G, Barbieri MA, Spina E, de Leon J (2019) A comprehensive review of swallowing difficulties and dysphagia associated with antipsychotics in adults. Expert Rev Clin Pharmacol 12, 219–234.
    OpenUrlPubMed
  235. [235].↵
    Strand LI, Gundrosen KF, Lein RK, Laekeman M, Lobbezoo F, Defrin R, Husebo BS (2019) Body movements as pain indicators in older people with cognitive impairment: A systematic review. Eur J Pain 23, 669–685.
    OpenUrl
  236. [236].↵
    Laberge S, Crizzle AM (2019) A literature review of psychotropic medications and alcohol as risk factors for falls in community dwelling older adults. Clin Drug Investig 39, 117–139.
    OpenUrlCrossRefPubMed
  237. [237].↵
    Goerdten J, Čukić I, Danso SO, Carrière I, Muniz-Terrera G (2019) Statistical methods for dementia risk prediction and recommendations for future work: A systematic review. Alzheimers Dement (N Y) 5, 563–569.
    OpenUrl
  238. [238].↵
    Dasgupta M, Hillier LM (2010) Factors associated with prolonged delirium: a systematic review. Int Psychogeriatr 22, 373–394.
    OpenUrlCrossRefPubMedWeb of Science
  239. [239].
    Xia C, Vonder M, Sidorenkov G, Oudkerk M, de Groot JC, van der Harst P, de Bock GH, De Deyn PP, Vliegenthart R (2020) The relationship of coronary artery calcium and clinical coronary artery disease with cognitive function: A systematic review and meta-analysis. J Atheroscler Thromb 27, 934–958.
    OpenUrl
  240. [240].↵
    Hughes TM, Rosano C, Evans RW, Kuller LH (2013) Brain cholesterol metabolism, oxysterols, and dementia. J Alzheimers Dis 33, 891–911.
    OpenUrl
  241. [241].↵
    Papathanasiou ND, Boutsiadis A, Dickson J, Bomanji JB (2012) Diagnostic accuracy of 123I-FP-CIT (DaTSCAN) in dementia with Lewy bodies: a meta-analysis of published studies. Parkinsonism Relat Disord 18, 225–229.
    OpenUrlCrossRefPubMedWeb of Science
  242. [242].↵
    Orgeta V, Leung P (2015) Personality and dementia caring: a review and commentary. Curr Opin Psychiatry 28, 57–65.
    OpenUrl
  243. [243].↵
    Wang H-X, Xu W, Pei J-J (2012) Leisure activities, cognition and dementia. Biochim Biophys Acta 1822, 482–491.
    OpenUrlCrossRefPubMedWeb of Science
  244. [244].↵
    Widmayer S, Borgwardt S, Lang UE, Huber CG (2019) Could animal-assisted therapy help to reduce coercive treatment in psychiatry? Front Psychiatry 10, 794.
    OpenUrl
  245. [245].↵
    Wong RMY, Chong KC, Law SW, Ho WT, Li J, Chui CS, Chow SKH, Cheung WH (2020) The effectiveness of exercises on fall and fracture prevention amongst community elderlies: A systematic review and meta-analysis. J Orthop Translat 24, 58–65.
    OpenUrl
  246. [246].↵
    Dyer SM, Laver K, Friel M, Whitehead C, Crotty M (2017) The diagnostic accuracy of the Kimberley Indigenous Cognitive Assessment (KICA) tool: a systematic review. Australas Psychiatry 25, 282–287.
    OpenUrl
  247. [247].↵
    Baiano C, Barone P, Trojano L, Santangelo G (2020) Prevalence and clinical aspects of mild cognitive impairment in Parkinson’s disease: A meta-analysis. Mov Disord 35, 45–54.
    OpenUrlCrossRef
  248. [248].↵
    Aarsland D, Sardahaee FS, Anderssen S, Ballard C, Alzheimer’s Society Systematic Review group (2010) Is physical activity a potential preventive factor for vascular dementia? A systematic review. Aging Ment Health 14, 386–395.
    OpenUrlCrossRefPubMedWeb of Science
  249. [249].↵
    Musa MK, Saga S, Blekken LE, Harris R, Goodman C, Norton C (2019) The prevalence, incidence, and correlates of fecal incontinence among older people residing in care homes: A systematic review. J Am Med Dir Assoc 20, 956–962.e8.
    OpenUrlPubMed
  250. [250].↵
    Serafini G, Calcagno P, Lester D, Girardi P, Amore M, Pompili M (2016) Suicide risk in Alzheimer’s disease: A systematic review. Curr Alzheimer Res 13, 1083–1099.
    OpenUrl
  251. [251].↵
    Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: Evidence Report and Systematic Review for the US Preventive … Show all.
  252. [252].↵
    Lang L, Clifford A, Wei L, Zhang D, Leung D, Augustine G, Danat IM, Zhou W, Copeland JR, Anstey KJ, Chen R (2017) Prevalence and determinants of undetected dementia in the community: a systematic literature review and a meta-analysis. BMJ Open 7, e011146.
    OpenUrl
  253. [253].
    Sommer I, Griebler U, Kien C, Auer S, Klerings I, Hammer R, Holzer P, Gartlehner G (2017) Vitamin D deficiency as a risk factor for dementia: a systematic review and meta-analysis. BMC Geriatr 17, 16.
    OpenUrl
  254. [254].
    O’ Brien H, Mohan H, Hare CO, Reynolds JV, Kenny RA (2017) Mind over matter? The hidden epidemic of cognitive dysfunction in the older surgical patient. Ann Surg 265, 677– 691.
    OpenUrlCrossRefPubMed
  255. [255].↵
    Hua Y, Guo X, Huang Q, Kong Y, Lu X (2013) Association between interleukin-6 – 174G/C polymorphism and the risk of Alzheimer’s disease: a meta-analysis. Int J Neurosci 123, 626–635.
    OpenUrl
  256. [256].↵
    Saini RK, Rengasamy KRR, Mahomoodally FM, Keum Y-S (2020) Protective effects of lycopene in cancer, cardiovascular, and neurodegenerative diseases: An update on epidemiological and mechanistic perspectives. Pharmacol Res 155, 104730.
    OpenUrl
  257. [257].↵
    Angehrn Z, Sostar J, Nordon C, Turner A, Gove D, Karcher H, Keenan A, Mittelstadt B, de Reydet-de Vulpillieres F (2020) Ethical and social implications of using predictive modeling for Alzheimer’s disease prevention: A systematic literature review. J Alzheimers Dis 76, 923–940.
    OpenUrl
  258. [258].
    Colucci L, Bosco M, Rosario Ziello A, Rea R, Amenta F, Fasanaro AM (2012) Effectiveness of nootropic drugs with cholinergic activity in treatment of cognitive deficit: a review. J Exp Pharmacol 4, 163–172.
    OpenUrl
  259. [259].
    Montgomery W, Ueda K, Jorgensen M, Stathis S, Cheng Y, Nakamura T (2018) Epidemiology, associated burden, and current clinical practice for the diagnosis and management of Alzheimer’s disease in Japan. Clinicoecon Outcomes Res 10, 13–28.
    OpenUrl
  260. [260].↵
    Xu W, Tan L, Wang H-F, Jiang T, Tan M-S, Tan L, Zhao Q-F, Li J-Q, Wang J, Yu J-T (2015) Meta-analysis of modifiable risk factors for Alzheimer’s disease. J Neurol Neurosurg Psychiatry 86, 1299–1306.
    OpenUrlAbstract/FREE Full Text
  261. [261].↵
    Peters R, Ee N, Peters J, Beckett N, Booth A, Rockwood K, Anstey KJ (2019) Common risk factors for major noncommunicable disease, a systematic overview of reviews and commentary: the implied potential for targeted risk reduction. Ther Adv Chronic Dis 10, 2040622319880392.
    OpenUrlPubMed
  262. [262].↵
    Waters DD (2010) Exploring new indications for statins beyond atherosclerosis: Successes and setbacks. J Cardiol 55, 155–162.
    OpenUrlCrossRefPubMedWeb of Science
  263. [263].
    Russ TC, Starr JM, Stamatakis E, Kivimäki M, Batty GD (2015) Pulmonary function as a risk factor for dementia death: an individual participant meta-analysis of six UK general population cohort studies. J Epidemiol Community Health 69, 550–556.
    OpenUrlAbstract/FREE Full Text
  264. [264].↵
    Tobore TO (2019) On the central role of mitochondria dysfunction and oxidative stress in Alzheimer’s disease. Neurol Sci 40, 1527–1540.
    OpenUrl
  265. [265].
    Cipriani G, Danti S, Vedovello M, Nuti A, Lucetti C (2014) Understanding delusion in dementia: a review. Geriatr Gerontol Int 14, 32–39.
    OpenUrlCrossRefPubMed
  266. [266].↵
    Guio D, François M, Duering F, Fazekas F-ED, Leeuw SM, Greenberg L, Pantoni A, Aghetti EE, Smith J, Wardlaw E (2020) Brain Atrophy in Cerebral Small Vessel Diseases: Extent, Consequences, Technical Limitations and Perspectives: The HARNESS Initiative. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism 40, 231–245.
    OpenUrl
  267. [267].↵
    McDonald C, Newton JL, Burn DJ (2016) Orthostatic hypotension and cognitive impairment in Parkinson’s disease: Causation or association? Mov Disord 31, 937–946.
    OpenUrlCrossRefPubMed
  268. [268].
    Lemche E (2018) Early Life Stress and epigenetics in Late-onset Alzheimer’s dementia: A systematic review. Curr Genomics 19, 522–602.
    OpenUrl
  269. [269].↵
    Arvãtescu C, Moga MA, Mironescu A, Æamota I, Dracea L (2015) Hormone replacement therapy (hrt) in menopause. estetrol and brain. 50, 418–421.
    OpenUrl
  270. [270].↵
    Hersi M, Irvine B, Gupta P, Gomes J, Birkett N, Krewski D (2017) Risk factors associated with the onset and progression of Alzheimer’s disease: A systematic review of the evidence. Neurotoxicology 61, 143–187.
    OpenUrlCrossRef
  271. [271].↵
    Gunnarsson L-G, Bodin L (2019) Occupational exposures and neurodegenerative diseases-A systematic literature review and meta-analyses. Int J Environ Res Public Health 16, 337.
    OpenUrl
  272. [272].↵
    National Institute on Aging, NIA Alzheimer’s Disease Genetics Portfolio, Last updated 2023, Accessed on 2023.
  273. [273].↵
    National Institute on Aging, NIA data LINKAGE Program (LINKAGE), Last updated 2023, Accessed on 2023.
  274. [274].↵
    Chuang Y-N, Wang G, Chang C-Y, Lai K-H, Zha D, Tang R, Yang F, Reyes AC, Zhou K, Jiang X, Hu X (2023) DiscoverPath: A knowledge refinement and retrieval system for interdisciplinarity on biomedical research. In Proceedings of the 32nd ACM International Conference on Information and Knowledge Management ACM, New York, NY, USA.
  275. [275].↵
    Ureña-Guerrero ME, Castañeda-Cabral JL, Rivera-Cervantes MC, Macias-Velez RJ, Jarero-Basulto JJ, Gudiño-Cabrera G, Beas-Zárate C (2020) Neuroprotective and neurorestorative effects of Epo and VEGF: Perspectives for new therapeutic approaches to neurological diseases. Curr Pharm Des 26, 1263–1276.
    OpenUrl
Back to top
Posted February 21, 2024.
Download PDF
Data/Code
Email
Feasibility of Identifying Factors Related to Alzheimer’s Disease and Related Dementia in Real-World Data
Aokun Chen, Qian Li, Yu Huang, Yongqiu Li, Yu-neng Chuang, Xia Hu, Serena Guo, Yonghui Wu, Yi Guo, Jiang Bian
medRxiv 2024.02.10.24302621; doi: https://doi.org/10.1101/2024.02.10.24302621
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area